1
|
Farge D, Pugnet G, Allez M, Castilla-Llorente C, Chatelus E, Cintas P, Faucher-Barbey C, Labauge P, Labeyrie C, Lioure B, Maria A, Michonneau D, Puyade M, Talouarn M, Terriou L, Treton X, Wojtasik G, Zephir H, Marjanovic Z. French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases. Rev Med Interne 2024; 45:79-99. [PMID: 38220493 DOI: 10.1016/j.revmed.2023.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Accepted: 12/29/2023] [Indexed: 01/16/2024]
Abstract
Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25years and is now validated by national and international medical societies for severe early systemic sclerosis (SSc) and relapsing-remitting multiple sclerosis (MS) and available as part of routine care in accredited center. HSCT is also recommended, with varying levels of evidence, as an alternative treatment for several ADs, when refractory to conventional therapy, including specific cases of connective tissue diseases or vasculitis, inflammatory neurological diseases, and more rarely severe refractory Crohn's disease. The aim of this document was to provide guidelines for the current indications, procedures and follow-up of HSCT in ADs. Patient safety considerations are central to guidance on patient selection and conditioning, always validated at the national MATHEC multidisciplinary team meeting (MDTM) based on recent (less than 3months) thorough patient evaluation. HSCT procedural aspects and follow-up are then carried out within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and SFGM-TC accredited centres in close collaboration with the ADs specialist. These French recommendations were performed according to HAS/FAI2R standard operating procedures and coordinated by the Île-de-France MATHEC Reference Centre for Rare Systemic Autoimmune Diseases (CRMR MATHEC) within the Filière FAI2R and in association with the Filière MaRIH. The task force consisted of 3 patients and 64 clinical experts from various specialties and French centres. These data-derived and consensus-derived recommendations will help clinicians to propose HSCT for their severe ADs patients in an evidence-based way. These recommendations also give directions for future clinical research in this area. These recommendations will be updated according to newly emerging data. Of note, other cell therapies that have not yet been approved for clinical practice or are the subject of ongoing clinical research will not be addressed in this document.
Collapse
Affiliation(s)
- D Farge
- AP-HP, hôpital St-Louis, centre de référence des maladies auto-immunes systémiques rares d'Île-de-France MATHEC (FAI2R), unité de Médecine Interne (UF 04) : CRMR MATHEC, maladies auto-immunes et thérapie cellulaire (UF 04), 1, avenue Claude-Vellefaux, 75010 Paris, France; Université de Paris, IRSL, Recherche clinique appliquée à l'hématologie, URP-3518, 75010 Paris, France; Department of Medicine, McGill University, H3A 1A1, Montreal, Canada.
| | - G Pugnet
- Service de médecine interne et immunologie clinique, pôle hospitalo-universitaire des maladies digestives, CHU Rangueil, 1, avenue du Pr-Jean-Poulhès, 31059 Toulouse cedex 9, France
| | - M Allez
- AP-HP, hôpital Saint-Louis, service d'hépato-gastro-entérologie, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - C Castilla-Llorente
- Gustave-Roussy cancer center, département d'hématologie, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - E Chatelus
- Département de rhumatologie, hôpitaux universitaires de Strasbourg, Strasbourg, France; Centre de référence des maladies auto-immunes systémiques rares de l'Est et du Sud-Ouest, Strasbourg, France
| | - P Cintas
- CHU Toulouse Purpan, service de neurologie, place du Dr-Baylac, 31059 Toulouse cedex 9, France
| | - C Faucher-Barbey
- Direction prélèvements et greffes de CSH, Direction médicale et scientifique, Agence de la biomédecine, 93212 St-Denis/La Plaine, France
| | - P Labauge
- CRC SEP, service de neurologie, CHU de Montpellier, 34295 Montpellier cedex 5, France
| | - C Labeyrie
- AP-HP, CHU de Bicêtre, service de neurologie, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - B Lioure
- Département d'onco-hématologie, université de Strasbourg, ICANS, Strasbourg, France
| | - A Maria
- Médecine interne & immuno-oncologie (MedI2O), Institute for Regenerative Medicine & Biotherapy (IRMB), hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, Montpellier, France; IRMB, Inserm U1183, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France
| | - D Michonneau
- Université de Paris, IRSL, Recherche clinique appliquée à l'hématologie, URP-3518, 75010 Paris, France; Service d'hématologie-greffe, AP-HP, hôpital Saint-Louis, institut de recherche Saint-Louis, Paris, France
| | - M Puyade
- CHU de Poitiers, service de médecine interne, 2, rue de La-Miletrie, 86021 Poitiers, France
| | - M Talouarn
- AP-HP, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France
| | - L Terriou
- CHU de Lille, département de médecine interne et immunologie clinique, 59000 Lille, France; Centre de référence des maladies auto-immunes et auto-inflammatoires rares (CERAINO), 59000 Lille, France
| | - X Treton
- Université de Paris, hôpital Beaujon, service de gastro-entérologie, MICI et assistance nutritive, DMU DIGEST, 100, boulevard Leclerc, 92110 Clichy, France
| | - G Wojtasik
- Université de Lille, Inserm, CHU de Lille, service de médecine interne et immunologie clinique, Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), U1286 - INFINITE - Institut de recherche translationnelle sur l'inflammation, Lille, France
| | - H Zephir
- CHU de Lille, université de Lille, pôle des neurosciences et de l'appareil locomoteur, Lille Inflammation Research International Center (LIRIC), UMR 995, rue Émile-Laine, 59000 Lille, France
| | - Z Marjanovic
- AP-HP, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France
| |
Collapse
|
2
|
Coustal C, Goulabchand R, Labauge P, Guilpain P, Carra-Dallière C, Januel E, Jeziorski E, Salle V, Viallard J, Boutboul D, Fieschi C, Gobert D, Aladjidi N, Rullier P, Graveleau J, Piel-Julian M, Suarez F, Neven B, Mahlaoui N, Ayrignac X. Atteintes neurologiques multifacettes des déficits en CTLA4 : étude observationnelle nationale. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
3
|
Ciron J, Gueguen A, Al Khedr A, Bourre B, Clavelou P, Defer G, Durand-Dubief F, Labauge P, Ouallet JC, Pittion Vouyovitch S, Tourbah A, Vermersch P. Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria. Rev Neurol (Paris) 2022; 178:1098-1104. [PMID: 36180289 DOI: 10.1016/j.neurol.2022.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 06/15/2022] [Accepted: 07/04/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND In clinical practice, the diagnosis of secondary progressive multiple sclerosis (SPMS) is often delayed, retrospective and non-reproducible, as there are no consensus criteria that define the advent of SPMS. Early identification of SPMS is essential to improve patient care. METHODS Eight regional board meetings in France involving 56 multiple sclerosis (MS) experts (neurologists) were convened to discuss diagnostic criteria for SPMS. Subsequently, a national board meeting of 13 neurologists (with an expert representing each geographical region) was held to review points of convergence or divergence between regions and to develop a national consensus document. RESULTS Based on the discussions from the regional boards, the MS experts at the national board retained the worsening of the EDSS score, with compatible clinical features, as the only consensus criterion for the diagnosis of SPMS in clinical practice. The patient should have experienced during at least the previous 6 months and in the absence of any relapse, a worsening in the EDSS score of +1.0 point (if the previous EDSS was≤5.0) or of +0.5 point (if the previous EDSS was≥5.5), with a pyramidal or cerebellar functional system score≥2 and without setting a minimum EDSS score; or, in case of a stable EDSS score≥4.0, a worsening of a functional score. This worsening should be confirmed within 3 to 6 months. According to the MS experts, the patient's age, duration of illness and a minimal threshold EDSS score are only risk factors for transition to SPMS. Patient reports during consultation and cognitive impairment are important warning signs, which should trigger an objective assessment with specific tests or closer monitoring. Clinical relapse and/or MRI activities are non-discriminatory for making the diagnosis of SPMS. CONCLUSIONS The experts defined precise diagnostic criteria adapted to clinical practice for earlier identification of SPMS, paving the way for better management of this stage of the disease.
Collapse
Affiliation(s)
- J Ciron
- Département de neurologie, CRC-SEP, CHU de Toulouse, place du Dr-Baylac, 31059 Toulouse cedex 9, France.
| | - A Gueguen
- Fondation ophtalmologique Adolphe de Rothschild, 29, rue Manin, Paris, France
| | - A Al Khedr
- CHU d'Amiens, 2, place Victor-Pauchet, Amiens, France
| | - B Bourre
- CHU de Rouen, 76000 Rouen, France
| | - P Clavelou
- CHU de Clermont-Ferrand, 58, rue Montalembert, Clermont-Ferrand, France
| | - G Defer
- CRC-SEP, service de neurologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France
| | - F Durand-Dubief
- Service de sclérose en plaques, pathologies de la myéline et neuro-inflammation, hôpital neurologique, GHE, 59, boulevard Pinel, 69677 Bron Lyon cedex, France
| | - P Labauge
- CRC-SEP, département de neurologie, CHU de Montpellier, 80, avenue G.-Fliche, 34295 Montpellier cedex 5, France
| | - J-C Ouallet
- Service de neurologie et maladies inflammatoires du système nerveux central, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | | | - A Tourbah
- UFR Simone Veil, UVSQ, Inserm U 1195, service de neurologie, hôpital Raymond Poincaré, université Paris Saclay, AP-HP, Garches, France
| | - P Vermersch
- Inserm U1172 - Lille neuroscience et cognition, FHU Imminent, université de Lille, CHU Lille, 59000 Lille, France
| |
Collapse
|
4
|
Grangeon L, Quesney G, Verdalle-Cazes M, Coulette S, Renard D, Wacongne A, Allou T, Olivier N, Boukriche Y, Blanchet-Fourcade G, Labauge P, Arquizan C, Canaple S, Godefroy O, Martinaud O, Verdure P, Quillard-Muraine M, Pariente J, Magnin E, Nicolas G, Charbonnier C, Maltête D, Formaglio M, Raposo N, Ayrignac X, Wallon D. Different clinical outcomes between cerebral amyloid angiopathy-related inflammation and non-inflammatory form. J Neurol 2022; 269:4972-4984. [PMID: 35752990 DOI: 10.1007/s00415-022-11145-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Revised: 04/12/2022] [Accepted: 04/13/2022] [Indexed: 10/17/2022]
Abstract
OBJECTIVE Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a rare manifestation related to CAA, thought to be more severe. We aimed to compare the clinical and radiological outcomes of CAA-ri and non-inflammatory CAA. MATERIALS AND METHODS We retrospectively included all patients with CAA-ri from 13 French centers. We constituted a sex- and age-matched control cohort with non-inflammatory CAA and similar disease duration. Survival, autonomy and cognitive evolution were compared after logistic regression. Cerebral microbleeds (CMB), intracerebral hemorrhage, cortical superficial siderosis and hippocampal atrophy were analyzed as well as CSF biomarker profile and APOE genotype when available. Outcomes were compared using Kaplan-Meier curves and log-rank tests. RESULTS Data from 48 CAA-ri patients including 28 already reported and 20 new patients were analyzed. Over a mean of 3.1 years, 11 patients died (22.9%) and 18 (37.5%) relapsed. CAA-ri patients were more frequently institutionalized than non-inflammatory CAA patients (30% vs 8.3%, p < 0.001); mortality rates remained similar. MMSE and modified Rankin scale scores showed greater severity in CAA-ri at last follow-up. MRI showed a higher number of CMB at baseline and last follow-up in CAA-ri (p < 0.001 and p = 0.004, respectively). CSF showed lower baseline levels of Aß42 in CAA-ri than non-inflammatory CAA (373.3 pg/ml vs 490.8 pg/ml, p = 0.05). CAA-ri patients more likely carried at least one APOE ε4 allele (76% vs 37.5%, adjusted p = 0.05) particularly as homozygous status (56% vs 6.2%, p < 0.001). INTERPRETATION CAA-ri appears to be more severe than non-inflammatory CAA with a significant loss of autonomy and global higher amyloid burden, shown by more CMB and a distinct CSF profile. This burden may be partially promoted by ε4 allele.
Collapse
Affiliation(s)
- L Grangeon
- Department of Neurology, Rouen University Hospital, 76031, Rouen, France.
| | - G Quesney
- Department of Neurology, Rouen University Hospital, 76031, Rouen, France
| | - M Verdalle-Cazes
- Department of Radiology, Rouen University Hospital, Rouen, France
| | - S Coulette
- Department of Neurology, INM, Univ Montpellier, INSERM, Montpellier University Hospital, Montpellier, France
| | - D Renard
- Department of Neurology, Nimes University Hospital, Nimes, France
| | - A Wacongne
- Department of Neurology, Nimes University Hospital, Nimes, France
| | - T Allou
- Department of Neurology, Perpignan Hospital, Perpignan, France
| | - N Olivier
- Department of Neurology, Perpignan Hospital, Perpignan, France
| | - Y Boukriche
- Department of Neurology, Beziers Hospital, Beziers, France
| | | | - P Labauge
- Department of Neurology, INM, Univ Montpellier, INSERM, Montpellier University Hospital, Montpellier, France
| | - C Arquizan
- Department of Neurology, INM, Univ Montpellier, INSERM, Montpellier University Hospital, Montpellier, France
| | - S Canaple
- Department of Neurology and Functional Neuroscience, Lab (UR UPJV 4559), Amiens University Hospital and University of Picardy Jules Verne, Amiens, France
| | - O Godefroy
- Department of Neurology and Functional Neuroscience, Lab (UR UPJV 4559), Amiens University Hospital and University of Picardy Jules Verne, Amiens, France
| | - O Martinaud
- Department of Neurology, Caen University Hospital, Caen, France.,EPHE, INSERM, U1077, CHU de Caen, Neuropsychologie Et Imagerie de La Mémoire Humaine, Normandie Univ, UNICAEN, PSL Research University, Caen, France
| | - P Verdure
- Department of Neurology, Les Feugrais Hospital, Elbeuf, France
| | - M Quillard-Muraine
- Laboratoire de Biochimie, Rouen University Hospital and University of Rouen, Rouen, France
| | - J Pariente
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier, Universitaire de Toulouse, Toulouse, France
| | - E Magnin
- Department of Neurology, Besancon Hospital, Besancon, France
| | - G Nicolas
- INSERM U1245, IRIB, Normandy University, CNR-MAJ, Rouen University Hospital, Rouen, France
| | - C Charbonnier
- INSERM U1245, IRIB, Normandy University, CNR-MAJ, Rouen University Hospital, Rouen, France
| | - D Maltête
- Department of Neurology, Rouen University Hospital, 76031, Rouen, France
| | - M Formaglio
- Department of Neurology, Lyon University Hospital, Lyon, France
| | - N Raposo
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier, Universitaire de Toulouse, Toulouse, France
| | - X Ayrignac
- Department of Neurology, INM, Univ Montpellier, INSERM, Montpellier University Hospital, Montpellier, France
| | - D Wallon
- Department of Neurology, Rouen University Hospital, 76031, Rouen, France.,Department of Neurology, Besancon Hospital, Besancon, France
| |
Collapse
|
5
|
Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Ben Nasr H, Hankiewicz K, Pottier C, Maubeuge N, Dimitri-Boulos D, Nifle C, Laplaud DA, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Karabudak R, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Koch-Henriksen N, Sellebjerg F, Soerensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, Leray E. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC Med Res Methodol 2022; 22:155. [PMID: 35637426 PMCID: PMC9150358 DOI: 10.1186/s12874-022-01623-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 04/25/2022] [Indexed: 11/18/2022] Open
Abstract
Background Natalizumab and fingolimod are used as high-efficacy treatments in relapsing–remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. Methods Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. Results Overall, 5,148 relapsing–remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. Conclusions This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is fulfilled. Supplementary Information The online version contains supplementary material available at 10.1186/s12874-022-01623-8.
Collapse
Affiliation(s)
- M Lefort
- Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Univ Rennes, EHESP, CNRS, Inserm, Rennes, France.,Univ Rennes, CHU Rennes, Investigation Clinique de Rennes)], CIC 1414 [(Centre d, 35000, InsermRennes, France
| | - S Sharmin
- Department of Medicine, University of Melbourne, Melbourne, Australia.,Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia
| | - J B Andersen
- Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Rigshospitalet Glostrup, Denmark
| | - S Vukusic
- Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677, Lyon/Bron, France.,Centre Des Neurosciences de Lyon, UMR5292, Observatoire Français de La Sclérose en Plaques, INSERM, 1028 et CNRS, 69003, Lyon, France.,Université, Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69000, Lyon, France
| | - R Casey
- Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677, Lyon/Bron, France.,Centre Des Neurosciences de Lyon, UMR5292, Observatoire Français de La Sclérose en Plaques, INSERM, 1028 et CNRS, 69003, Lyon, France.,Université, Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69000, Lyon, France.,Eugene Devic EDMUS Foundation, 69677, Lyon/Bron, France
| | - M Debouverie
- Centre Hospitalier Régional Universitaire de Nancy, Hôpital Central, Service de neurologie, Nancy, France
| | - G Edan
- Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Service de neurologie, Rennes, France
| | - J Ciron
- Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, CRC-SEP, Département de neurologie, Toulouse, France
| | - A Ruet
- Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Service de neurologie, Bordeaux, France
| | - J De Sèze
- Service des maladies inflammatoires du système nerveux - neurologie, centre d'investigation clinique de Strasbourg, Hôpitaux Universitaire de Strasbourg, Hôpital de Hautepierre, INSERM 1434, Strasbourg, France
| | - E Maillart
- Assistance Publique Des Hôpitaux de Paris, Hôpital de La Pitié-Salpêtrière, Service de neurologie, Paris, France
| | - H Zephir
- Centre Hospitalier Universitaire de Lille, Hôpital Salengro, Service de neurologie D, Lille, France
| | - P Labauge
- Centre Hospitalier Universitaire de Montpellier, Hôpital Gui de Chauliac, Service de neurologie, Montpellier, France
| | - G Defer
- Centre Hospitalier Universitaire de Caen Normandie, Hôpital Côte de Nacre, Service de neurologie, Caen, France
| | - C Lebrun-Frenay
- Centre Hospitalier Universitaire de Nice, UR2CA-URRIS,, Université Nice Côte d'Azur, Hôpital, Pasteur 2, Service de neurologie, Nice, France
| | - T Moreau
- Centre Hospitalier Universitaire Dijon Bourgogne, Hôpital François Mitterrand, Maladies Inflammatoires du Système Nerveux Et Neurologie Générale, Service de neurologie, Dijon, France
| | - E Berger
- Centre Hospitalier Régional Universitaire de Besançon, Hôpital Jean Minjoz, Service de neurologie, Besançon, France
| | - P Clavelou
- Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel-Montpied, Service de neurologie, Clermont-Ferrand, France
| | - J Pelletier
- Service de Neurologie, Aix Marseille Univ, APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, 13005, Marseille, France
| | - B Stankoff
- Assistance Publique Des Hôpitaux de Paris, Hôpital Saint-Antoine, Service de neurologie, Paris, France
| | - O Gout
- Fondation Adolphe de Rothschild de L'œil Et du Cerveau, Service de neurologie, Paris, France
| | - E Thouvenot
- Centre Hospitalier Universitaire de Nîmes, Hôpital Carémeau, Service de neurologie, Nîmes, France
| | - O Heinzlef
- Centre Hospitalier Intercommunal de Poissy Saint-Germain-en-Laye, Service de neurologie, Poissy, France
| | - A Al-Khedr
- Centre Hospitalier Universitaire d'Amiens Picardie, Site sud, Service de neurologie, Amiens, France
| | - B Bourre
- Rouen University Hospital, 76000, Rouen, France
| | - O Casez
- Centre Hospitalier Universitaire Grenoble-Alpes, Site nord, Service de neurologie, Grenoble/La Tronche, France
| | - P Cabre
- Centre Hospitalier Universitaire de Martinique, Hôpital Pierre Zobda-Quitman, Service de neurologie, Fort-de-France, France
| | - A Montcuquet
- Centre Hospitalier Universitaire Limoges, Hôpital Dupuytren, Service de neurologie, Limoges, France
| | - A Wahab
- Assistance Publique Des Hôpitaux de Paris, Hôpital Henri Mondor, Service de neurologie, Créteil, France
| | - J P Camdessanché
- Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Service de neurologie, Saint-Étienne, France
| | - A Maurousset
- Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, Service de neurologie, Tours, France
| | - H Ben Nasr
- Centre Hospitalier Sud Francilien, Service de neurologie, Corbeil-Essonnes, France
| | - K Hankiewicz
- Centre Hospitalier de Saint-Denis, Hôpital Casanova, Service de neurologie, Saint-Denis, France
| | - C Pottier
- Centre Hospitalier de Pontoise, Service de neurologie, Pontoise, France
| | - N Maubeuge
- Centre Hospitalier Universitaire de Poitiers, Site de La Milétrie, Service de neurologie, Poitiers, France
| | - D Dimitri-Boulos
- Assistance Publique Des Hôpitaux de Paris, Hôpital Bicêtre, Service de neurologie, Le Kremlin-Bicêtre, France
| | - C Nifle
- Centre Hospitalier de Versailles, Hôpital André-Mignot, Service de neurologie, Le Chesnay, France
| | - D A Laplaud
- CHU de Nantes, Service de Neurologie & CIC015 INSERM, 44093, Nantes, France.,INSERM CR1064, 44000, Nantes, France
| | - D Horakova
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
| | - E K Havrdova
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
| | - R Alroughani
- Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait
| | - G Izquierdo
- Hospital Universitario Virgen Macarena, Seville, Spain
| | - S Eichau
- Hospital Universitario Virgen Macarena, Seville, Spain
| | - S Ozakbas
- Dokuz Eylul University, Konak/Izmir, Turkey
| | - F Patti
- GF Ingrassia Department, University of Catania, Catania, Italy.,Policlinico G Rodolico, Catania, Italy
| | - M Onofrj
- Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy
| | - A Lugaresi
- Dipartimento Di Scienze Biomediche E Neuromotorie, Università Di Bologna, Bologna, Italy.,IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Bologna, Italy
| | - M Terzi
- Medical Faculty, 19 Mayis University, Samsun, Turkey
| | - P Grammond
- CISSS Chaudiere-Appalache, Levis, Canada
| | | | - B Yamout
- Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon
| | - A Prat
- Hopital Notre Dame, Montreal, Canada.,CHUM and Universite de Montreal, Montreal, Canada
| | - M Girard
- Hopital Notre Dame, Montreal, Canada.,CHUM and Universite de Montreal, Montreal, Canada
| | - P Duquette
- Hopital Notre Dame, Montreal, Canada.,CHUM and Universite de Montreal, Montreal, Canada
| | - C Boz
- KTU Medical Faculty Farabi Hospital, Trabzon, Turkey
| | - M Trojano
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy
| | - P McCombe
- University of Queensland, Brisbane, Australia.,Royal Brisbane and Women's Hospital, Herston, Australia
| | - M Slee
- Flinders University, Adelaide, Australia
| | - J Lechner-Scott
- School of Medicine and Public Health, University Newcastle, Newcastle, Australia.,Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia
| | - R Turkoglu
- Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
| | - P Sola
- Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy
| | - D Ferraro
- Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy
| | - F Granella
- Department of Medicine and Surgery, University of Parma, Parma, Italy.,Department of Emergency and General Medicine, Parma University Hospital, Parma, Italy
| | | | - J Prevost
- CSSS Saint-Jérôme, Saint-Jerome, Canada
| | | | - O Skibina
- Monash University, Melbourne, Australia
| | - K Buzzard
- Monash University, Melbourne, Australia
| | | | | | - B Van Wijmeersch
- Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, Belgium
| | - T Csepany
- Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - D Spitaleri
- Azienda Ospedaliera Di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy
| | - S Vucic
- Westmead Hospital, Sydney, Australia
| | - N Koch-Henriksen
- Department of Clinical Epidemiology, Aarhus University Hospital Aarhus, Aarhus, Denmark
| | - F Sellebjerg
- Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark
| | - P S Soerensen
- Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark
| | - C C Hilt Christensen
- Department of Neurology, Aalborg University Hospital, Multiple Sclerosis Unit, Aalborg, Denmark
| | - P V Rasmussen
- Aarhus University Hospital, Neurology, PJJ Boulevard, DK-8200, Aarhus N, Denmark
| | - M B Jensen
- Department of Neurology, University Hospital of Northern Sealand, Copenhagen, Denmark
| | - J L Frederiksen
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - S Bramow
- Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark
| | - H K Mathiesen
- Department of Neurology, Copenhagen University Hospital Herlev, Copenhagen, Denmark
| | - K I Schreiber
- Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark
| | - H Butzkueven
- Central Clinical School, Monash University, Melbourne, Australia.,Department of Neurology, The Alfred Hospital, Melbourne, Australia.,Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia
| | - M Magyari
- Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.,Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark
| | - T Kalincik
- Department of Medicine, University of Melbourne, Melbourne, Australia.
| | - E Leray
- Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Univ Rennes, EHESP, CNRS, Inserm, Rennes, France. .,Univ Rennes, CHU Rennes, Investigation Clinique de Rennes)], CIC 1414 [(Centre d, 35000, InsermRennes, France.
| |
Collapse
|
6
|
Bouleau A, Dulong C, Schwerer CA, Delgrange R, Bouaou K, Brochu T, Zinai S, Švecová K, Sá MJ, Petropoulos A, Aly S, Labauge P. The socioeconomic impact of multiple sclerosis in France: Results from the PETALS study. Mult Scler J Exp Transl Clin 2022; 8:20552173221093219. [PMID: 35479962 PMCID: PMC9036344 DOI: 10.1177/20552173221093219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Accepted: 03/24/2022] [Indexed: 11/25/2022] Open
Abstract
Background Multiple sclerosis (MS) places a considerable financial burden on the society. However, data quantifying the contemporary cost burden in France are lacking. Objective This cost-of-illness study aimed to estimate the direct and indirect costs associated with MS in France. Methods Between October 2020-November 2020, 208 French adults with a confirmed diagnosis of MS were recruited via MSCopilot® (a new MS self-assessment digital solution) and several MS patient networks. Indirect costs were estimated using a combination of top-down and bottom-up approaches. Direct costs were retrieved from Assurance Maladie (i.e. national system of health insurance) publications. Out-of-pocket expenses (OOPEs) incurred by MS patients were also reported. All costs were expressed in €2020. Data from the survey were extrapolated to the overall French MS population. Results MS exerted an annual cost burden of €2.7 billion on the French society (indirect costs: €1.3 billion; direct costs: €1.4 billion). Mean annual costs were €27,164.7 per-patient, with indirect and direct costs accounting for 48.1% and 51.9% of the total annual costs, respectively. OOPEs contributed over €90 million to the total annual costs. Conclusions MS imposes a substantial cost burden on the French society, with approximately half of the total annual costs driven by indirect costs.
Collapse
Affiliation(s)
- A Bouleau
- Asterès Inc., Paris, France
- Ad Scientiam, Paris, France
| | - C Dulong
- Ad Scientiam, Paris, France
- Ad Scientiam, Paris, France
| | - CA Schwerer
- Asterès Inc., Paris, France
- Ad Scientiam, Paris, France
| | | | | | | | | | - K Švecová
- Independent HEOR Consultant, Zurich, Switzerland
| | - MJ Sá
- Centro Hospitalar Universitário de São João and Universidade Fernando Pessoa, Porto, Portugal
| | - A Petropoulos
- Novartis Hellas SACI, Athens, Greece
- Novartis Pharma AG, Basel, Switzerland
| | - S Aly
- Novartis Pharma AG, Basel, Switzerland
| | - P Labauge
- Département de Neurologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| |
Collapse
|
7
|
Ayrignac X, Zagroun C, Coget A, Azakri S, Menjot de Champfleur N, Montcriol AL, Labauge P, Mourand I, Ducros A, Daïen V, Arquizan C. Acute retinal arterial ischaemia: silent brain infarcts prevalence and short‐term recurrence. Eur J Neurol 2020; 27:2517-2522. [DOI: 10.1111/ene.14485] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Accepted: 08/15/2020] [Indexed: 11/29/2022]
Affiliation(s)
- X. Ayrignac
- Département de Neurologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - C. Zagroun
- Département d’Ophtalmologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - A. Coget
- Département de Neuroradiologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - S. Azakri
- Département de Neurologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | | | - A. L. Montcriol
- Département d’Ophtalmologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - P. Labauge
- Département de Neurologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - I. Mourand
- Département de Neurologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - A. Ducros
- Département de Neurologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - V. Daïen
- Département d’Ophtalmologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| | - C. Arquizan
- Département de Neurologie CHU Montpellier INSERM Univ Montpellier Montpellier France
| |
Collapse
|
8
|
Brisset JC, Kremer S, Hannoun S, Bonneville F, Durand-Dubief F, Tourdias T, Barillot C, Guttmann C, Vukusic S, Dousset V, Cotton F, Ameli R, Anxionnat R, Audoin B, Attye A, Bannier E, Barillot C, Ben Salem D, Boncoeur-Martel MP, Bonhomme G, Bonneville F, Boutet C, Brisset J, Cervenanski F, Claise B, Commowick O, Constans JM, Cotton F, Dardel P, Desal H, Dousset V, Durand-Dubief F, Ferre JC, Gaultier A, Gerardin E, Glattard T, Grand S, Grenier T, Guillevin R, Guttmann C, Krainik A, Kremer S, Lion S, Champfleur NMD, Mondot L, Outteryck O, Pyatigorskaya N, Pruvo JP, Rabaste S, Ranjeva JP, Roch JA, Sadik JC, Sappey-Marinier D, Savatovsky J, Stankoff B, Tanguy JY, Tourbah A, Tourdias T, Brochet B, Casey R, Cotton F, De Sèze J, Douek P, Guillemin F, Laplaud D, Lebrun-Frenay C, Mansuy L, Moreau T, Olaiz J, Pelletier J, Rigaud-Bully C, Stankoff B, Vukusic S, Debouverie M, Edan G, Ciron J, Lubetzki C, Vermersch P, Labauge P, Defer G, Berger E, Clavelou P, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Créange A, Camdessanché JP, Bakchine S, Maurousset A, Patry I, De Broucker T, Pottier C, Neau JP, Labeyrie C, Nifle C. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. J Neuroradiol 2020; 47:250-258. [DOI: 10.1016/j.neurad.2020.01.083] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 01/22/2020] [Accepted: 01/22/2020] [Indexed: 01/04/2023]
|
9
|
Labauge P. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? No. Rev Neurol (Paris) 2020; 176:494-496. [PMID: 32334842 DOI: 10.1016/j.neurol.2020.03.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Accepted: 11/13/2019] [Indexed: 11/16/2022]
Abstract
RR MS evolution has changed since the beginning of the availability of MS disease-modifying drugs (DMD). Before concluding a unique impact of the efficiency of DMD, careful analysis of long-term studies has to be conducted. Analysis of the literature points out a few bias in the long-term follow of MS patients under DMD: indication of DMD has changed since 20 years, diagnosis criteria are not the same (including the Will Rogers phenomen), and so far population are not homogeneous and comparable. Analysis criteria of the efficiency of the treatments are not the same, pending on the date of the publications. References concerning the long-term impact of DMD are in fact very limited. In addition, long-term efficiency of 2nd line treatments is not available. Another explanation of the change of MS evolution could be the lower evolutivity of MS patients since 2 decades. Analysis of placebo group in pivotal studies, argues to a decrease of the relapse annual rate and mean EDSS score in the more recent studies and recent MS diagnosed patients. To conclude, long-term evolution of MS patients is more favorable, influence of DMD is likely, but not unique.
Collapse
Affiliation(s)
- P Labauge
- CRC SEP, Department of Neurology, Montpellier University Hospital, CHU de Montpellier, 34295 Montpellier cedex 5, France.
| |
Collapse
|
10
|
Bigaut K, Lambert C, Kremer L, Lebrun C, Cohen M, Ciron J, Bourre B, Créange A, Kerschen P, Montcuquet A, Carra-Dalliere C, Ayrignac X, Labauge P, de Seze J, Collongues N. Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. Mult Scler 2020; 27:232-238. [DOI: 10.1177/1352458520906995] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: Atypical myelitis in multiple sclerosis (MS) is characterized by extensive myelitis in the longitudinal (longitudinally extensive transverse myelitis) or axial plane (transverse myelitis). Objective: To characterize a cohort of MS patients with atypical myelitis. Methods: Atypical myelitis was extracted from the French and Luxembourg MS databases and compared to two cohorts of MS patients with typical myelitis and neuromyelitis optica spectrum disorders (NMOSDs) patients with myelitis. Results: We enrolled 28 MS patients with atypical myelitis, 68 MS patients with typical myelitis and 119 NMOSD patients with a first episode of myelitis. MS patients with atypical myelitis were characterized by a mean age of 34.0 (±10.7) years and 64.3% were women. In 82.1% of the patients, atypical myelitis was the first episode of MS. Mean Expanded Disability Status Scale (EDSS) scores at nadir and 3–6 months after onset were 4.1 ± 2.1 and 3.3 ± 2, respectively. Differences between groups revealed a predominance of cervicothoracic myelitis and a higher level of disability in NMOSD patients. Disability in MS patients with atypical myelitis was more severe than in the MS patients with typical myelitis; 28% had already converted to progressive MS within our mean follow-up of 39.6 (±30.4) months. Conclusion: Atypical myelitis may be the first presentation of MS and is associated with poorer prognosis.
Collapse
Affiliation(s)
- K Bigaut
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - C Lambert
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - L Kremer
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - C Lebrun
- CRC-SEP, Neurologie, Université Nice Côte d’Azur, CHU Pasteur 2, Nice, France
| | - M Cohen
- CRC-SEP, Neurologie, Université Nice Côte d’Azur, CHU Pasteur 2, Nice, France
| | - J Ciron
- CRC-SEP, Neurologie, CHU Toulouse, Toulouse, France
| | - B Bourre
- Service de Neurologie, CHU de Rouen, Rouen, France
| | - A Créange
- Service de Neurologie, CHU de Créteil, Paris, France
| | - P Kerschen
- Service de Neurologie, Centre Hospitalier de Luxembourg, Luxembourg
| | - A Montcuquet
- Service de Neurologie, CHU de Limoges, Limoges, France
| | | | - X Ayrignac
- CRC-SEP, Neurologie, CHU de Montpellier, Montpellier, France
| | - P Labauge
- CRC-SEP, Neurologie, CHU de Montpellier, Montpellier, France
| | - J de Seze
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - N Collongues
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| |
Collapse
|
11
|
Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Mayran P, Bieuvelet S, Vallée M, Bertillot F, Klaeylé L, Argoud AL, Zinaï S, Tourbah A. MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. Eur J Neurol 2019; 27:429-436. [PMID: 31538396 DOI: 10.1111/ene.14091] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 07/24/2019] [Accepted: 09/09/2019] [Indexed: 01/09/2023]
Abstract
BACKGROUND AND PURPOSE Assessing patients' disability in multiple sclerosis (MS) requires time-consuming batteries of hospital tests. MSCopilot is a software medical device for the self-assessment of patients with MS (PwMS), combining four tests: walking, dexterity, cognition and low contrast vision. The objective was to validate MSCopilot versus the Multiple Sclerosis Functional Composite (MSFC). METHODS This multicentre, open-label, randomized, controlled, crossover study enrolled 141 PwMS and 76 healthy controls (HCs). All participants performed MSCopilot and MSFC tests at day 0. To assess reproducibility, 46 PwMS performed the same tests at day 30 ± 3. The primary end-point was the validation of MSCopilot versus MSFC for the identification of PwMS against HCs, quantified using the area under the curve (AUC). The main secondary end-point was the correlation of MSCopilot z-scores with MSFC z-scores. RESULTS In all, 116 PwMS and 69 HCs were analysed. The primary end-point was achieved: MSCopilot performance was non-inferior to that of MSFC (AUC 0.92 and 0.89 respectively; P = 0.3). MSCopilot and MSFC discriminated PwMS and HCs with 81% and 76% sensitivity and 82% and 88% specificity respectively. Digital and standard test scores were highly correlated (r = 0.81; P < 0.001). The test-retest study demonstrated the good reproducibility of MSCopilot. CONCLUSION This study confirms the reliability of MSCopilot and its usability in clinical practice for the monitoring of MS-related disability.
Collapse
Affiliation(s)
- E Maillart
- Department of Neurology, Pitié Salpêtrière Hospital, Paris, France
| | - P Labauge
- Department of Neurology, Montpellier University Hospital, Montpellier, France
| | - M Cohen
- Department of Neurology, Nice University Hospital, Nice, France
| | - A Maarouf
- CNRS, CRMBM, APHM, Aix-Marseille University, Marseille, France.,Pole de Neurosciences Cliniques, Marseille, France
| | - S Vukusic
- Department of Neurology, Hospices Civils de Lyon, Bron, France.,INSERM 1028 et CNRS UMR 5292, University Lyon 1, Lyon, France
| | - C Donzé
- Department of Physical and Rehabilitation Medicine, Groupe Hospitalier de l'Institut Catholique de Lille, Lille, France
| | - P Gallien
- Physical Rehabilitation Medicine, Pole Saint Helier, Rennes, France
| | - J De Sèze
- Department of Neurology, Hôpital Civil, Strasbourg University, Strasbourg, France
| | - B Bourre
- Department of Neurology, Rouen University Hospital, Rouen, France
| | - T Moreau
- Department of Neurology, Dijon University Hospital, Dijon, France
| | - C Louapre
- Department of Neurology, Pitié Salpêtrière Hospital, Paris, France
| | | | - S Bieuvelet
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - M Vallée
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - F Bertillot
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - L Klaeylé
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - A-L Argoud
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - S Zinaï
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - A Tourbah
- Department of Neurology, Reims University Hospital, URCA, Reims, France.,LPN EA, 2027 Paris 8 University, Saint-Denis, France.,Service de Neurologie, Hôpitaux universitaires paris-Ile-de-France Ouest, APHP, Université Versailles-Saint Quentin en Yvelines, Paris Saclay, France
| |
Collapse
|
12
|
Perez L, Foulongne V, Menjot De Champfleur N, Ceballos P, Labauge P, Reynes J, Guilpain P, Le Moing V. Épidémiologie de la leuco-encéphalopathie multifocale progressive à l’ère des biothérapies et des antirétroviraux. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Lebrun C, Vukusic S, Abadie V, Achour C, Ader F, Alchaar H, Alkhedr A, Andreux F, Androdias G, Arjmand R, Audoin B, Audry D, Aufauvre D, Autreaux C, Ayrignac X, Bailbe M, Benazet M, Bensa C, Bensmail D, Berger E, Bernady P, Bertagna Y, Biotti D, Blanchard-Dauphin A, Bonenfant J, Bonnan M, Bonnemain B, Borgel F, Botelho-Nevers E, Boucly S, Bourre B, Boutière C, Branger P, Brassat D, Bresch S, Breuil V, Brochet B, Brugeilles H, Bugnon P, Cabre P, Camdessanché JP, Carra-Dalière C, Casez O, Chamouard JM, Chassande B, Chataignier P, Chbicheb M, Chenet A, Ciron J, Clavelou P, Cohen M, Colamarino R, Collongues N, Coman I, Corail PR, Courtois S, Coustans M, Creange A, Creisson E, Daluzeau N, Davenas C, De Seze J, Debouverie M, Depaz R, Derache N, Divio L, Douay X, Dulau C, Durand-Dubief F, Edan G, Elias Z, Fagniez O, Faucher M, Faucheux JM, Fournier M, Gagneux-Brunon A, Gaida P, Galli P, Gallien P, Gaudelus J, Gault D, Gayou A, Genevray M, Gentil A, Gere J, Gignoux L, Giroux M, Givron P, Gout O, Grimaud J, Guennoc AM, Hadhoum N, Hautecoeur P, Heinzlef O, Jaeger M, Jeannin S, Kremer L, Kwiatkowski A, Labauge P, Labeyrie C, Lachaud S, Laffont I, Lanctin-Garcia C, Lannoy J, Lanotte L, Laplaud D, Latombe D, Lauxerois M, Le Page E, Lebrun-Frenay C, Lejeune P, Lejoyeux P, Lemonnier B, Leray E, Loche CM, Louapre C, Lubetzki C, Maarouf A, Mada B, Magy L, Maillart E, Manchon E, Marignier R, Marque P, Mathey G, Maurousset A, Mekies C, Merienne M, Michel L, Milor AM, Moisset X, Montcuquet A, Moreau T, Morel N, Moussa M, Naudillon JP, Normand M, Olive P, Ouallet JC, Outteryck O, Pacault C, Papeix C, Patry I, Peaureaux D, Pelletier J, Pichon B, Pittion S, Planque E, Pouget MC, Pourcher V, Radot C, Robert I, Rocher F, Ruet A, Ruet A, Saint-Val C, Salle JY, Salmon A, Sartori E, Schaeffer S, Stankhof B, Taithe F, Thouvenot E, Tizon C, Tourbah A, Tourniaire P, Vaillant M, Vermersch P, Vidil S, Wahab A, Warter MH, Wiertlewski S, Wiplosz B, Wittwer B, Zaenker C, Zephir H. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris) 2019; 175:341-357. [DOI: 10.1016/j.neurol.2019.04.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Revised: 03/31/2019] [Accepted: 04/11/2019] [Indexed: 10/26/2022]
|
14
|
Codjia P, Ayrignac X, Mochel F, Mouzat K, Carra-Dalliere C, Castelnovo G, Ellie E, Etcharry-Bouyx F, Verny C, Belliard S, Hannequin D, Marelli C, Nadjar Y, Le Ber I, Dorboz I, Samaan S, Boespflug-Tanguy O, Lumbroso S, Labauge P. Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia: An MRI Study of 16 French Cases. AJNR Am J Neuroradiol 2018; 39:1657-1661. [PMID: 30115677 DOI: 10.3174/ajnr.a5744] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2018] [Accepted: 05/01/2018] [Indexed: 11/07/2022]
Abstract
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia is an autosomal dominant leukoencephalopathy related to CSF1R gene mutations. A growing number of clinicoradiologic phenotypes have been described. In this study, we analyzed brain imaging findings in 16 patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia to refine radiologic diagnostic clues. T2/FLAIR white matter hyperintensities were present in all patients with frontal or frontoparietal predilection, with asymmetric distribution in more than one-third. Brain atrophy and callosal involvement were almost constant, and corticospinal tract involvement was frequent. Moreover, deep white matter hyperintense dots on DWI and deep punctate calcifications on CT were often found. Conversely, deep gray matter nuclei, external capsules, and brain stem were rarely involved. Our series emphasized the great variability of MR imaging findings seen in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. A complete imaging screening including DWI, T2*, and CT is mandatory to accurately assess patients with suspected inherited adult-onset leukoencephalopathy.
Collapse
Affiliation(s)
- P Codjia
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| | - X Ayrignac
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| | - F Mochel
- Genetics (F.M.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
| | - K Mouzat
- Departments of Biochemistry and Molecular Biology (K.M., S.L.)
| | - C Carra-Dalliere
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| | - G Castelnovo
- Neurology (G.C.), Nîmes University Hospital, Nîmes, France
| | - E Ellie
- Department of Neurology (E.E.), Côte Basque Hospital, Bayonne, France
| | - F Etcharry-Bouyx
- Department of Neurology (F.E.-B., C.V.), Angers University Hospital, Angers, France
| | - C Verny
- Department of Neurology (F.E.-B., C.V.), Angers University Hospital, Angers, France
| | - S Belliard
- Department of Neurology (S.B.), Rennes University Hospital, Rennes, France
| | - D Hannequin
- Department of Neurology (D.H.), Rouen University Hospital, Rouen, France
| | - C Marelli
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| | - Y Nadjar
- Departments of Neurology (Y.N., I.L.B.)
| | - I Le Ber
- Departments of Neurology (Y.N., I.L.B.)
| | - I Dorboz
- Department of Neuropediatrics and Metabolic Disorders (I.D., S.S., O.B.-T.), Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Paris, France
| | - S Samaan
- Department of Neuropediatrics and Metabolic Disorders (I.D., S.S., O.B.-T.), Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Paris, France
| | - O Boespflug-Tanguy
- Department of Neuropediatrics and Metabolic Disorders (I.D., S.S., O.B.-T.), Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Paris, France
| | - S Lumbroso
- Departments of Biochemistry and Molecular Biology (K.M., S.L.)
| | - P Labauge
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| |
Collapse
|
15
|
Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. J Neurol 2018; 265:2251-2259. [PMID: 30054790 DOI: 10.1007/s00415-018-8984-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Revised: 07/19/2018] [Accepted: 07/20/2018] [Indexed: 11/27/2022]
Abstract
BACKGROUND Tumefactive demyelinating lesions of the central nervous system can be the initial presentation in various pathological entities [multiple sclerosis (the most common), Balo's concentric sclerosis, Schilder's disease and acute disseminated encephalomyelitis] with overlapping clinical presentation. The aim of our study was to better characterize these patients. METHODS Eighty-seven patients (62 women and 25 men) from different MS centers in France were studied retrospectively. Inclusion criteria were (1) a first clinical event (2) MRI showing one or more large demyelinating lesions (20 mm or more in diameter) with mass-like features. Patients with a previous demyelinating event (i.e. confirmed multiple sclerosis) were excluded. RESULTS Mean age at onset was 26 years. The most common initial symptoms (67% of the patients) were hemiparesis or hemiplegia. Aphasia, headache and cognitive disturbances (i.e. atypical symptoms for demyelinating diseases) were observed in 15, 18 and 15% of patients, respectively. The mean largest diameter of the tumefactive lesions was 26.9 mm, with gadolinium enhancement in 66 patients (81%). Twenty-one patients (24%) had a single tumefactive lesion. During follow-up (median time 5.7 years) 4 patients died, 70 patients improved or remained stable and 12 worsened. 86% of patients received initial corticosteroid treatment, and 73% received disease-modifying therapy subsequently. EDSS at the end of the follow-up was 2.4 ± 2.6 (mean ± SD). CONCLUSION This study provides further evidence that the clinical course of MS presenting with large focal tumor-like lesions does not differ from that of classical relapsing-remitting MS, once the noisy first relapsing occurred.
Collapse
Affiliation(s)
- G Balloy
- Neurology Department, University of Nantes Hospital, Nantes, France. .,Service de Neurologie, Hopital Laennec, Boulevard Jacques Monod, 44800, Saint Herblain, France.
| | - J Pelletier
- Neurosciences Unit, Neurology Department, Timone Hospital, Aix Marseille University, APHM, Marseille, France
| | - L Suchet
- Neurosciences Unit, Neurology Department, Timone Hospital, Aix Marseille University, APHM, Marseille, France
| | - C Lebrun
- University of Nice Hospital, Nice, France
| | - M Cohen
- University of Nice Hospital, Nice, France
| | | | - H Zephir
- University of Lille Hospital, Lille, France
| | - E Duhin
- University of Lille Hospital, Lille, France
| | - O Gout
- Rothschild Foundation, Paris, France
| | | | - E Le Page
- University of Rennes Hospital, Rennes, France
| | - G Edan
- University of Rennes Hospital, Rennes, France
| | - P Labauge
- University of Montpellier Hospital, Montpellier, France
| | | | - L Rumbach
- University Besançon Hospital, Besançon, France
| | - E Berger
- University Besançon Hospital, Besançon, France
| | - P Lejeune
- La Roche sur Yon Hospital, La Roche-sur-Yon, France
| | - P Devos
- Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France
| | | | | | | | - B Daumas-Duport
- Radiology Department, University of Nantes Hospital, Nantes, France
| | - L Michel
- Neurology Department, University of Nantes Hospital, Nantes, France
| | - F Lefrere
- Neurology Department, University of Nantes Hospital, Nantes, France
| | - D A Laplaud
- Neurology Department, University of Nantes Hospital, Nantes, France
| | - C Brosset
- Military Hospital, Marseille, France
| | - P Derkinderen
- Neurology Department, University of Nantes Hospital, Nantes, France
| | - J de Seze
- University of Strasbourg Hospital, Strasbourg, France
| | - S Wiertlewski
- Neurology Department, University of Nantes Hospital, Nantes, France
| | | |
Collapse
|
16
|
Laplaud DA, Barbin L, Casey R, Debouverie M, Vukusic S, Labauge P, Brassat D, Wiertlewski S, De Seze J, Edan G, Brochet B, Moreau T, Berger E, Clavelou P, Castelnovo G, Ciron J, Pelletier J, Bourre B, Lubetzki C, Al Khedr A, Vermersch P, Lebrun-Frenay C, Defer G, Tourbah A, Camdessanche JP, Stankoff B, Labeyrie C, Patry I, Creange A, Gout O, Heinzlef O, Casez O, Magy L, Guennoc AM, De Broucker T, Nifle C, Dupel-Pottier C, Leray E, Rollot F, Foucher Y. Efficacité comparée du Teriflunomide et du Dimethyl-Fumarate : une étude observationnelle française multicentrique. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
17
|
Denève M, Biotti D, Dumas H, Patsoura S, Ferrier M, Meluchova Z, Mahieu L, Heran F, Vignal C, Deschamps R, Gout O, Menjot de Champfleur N, Ayrignac X, Dallière C, Labauge P, Cognard C, Brassat D, Bonneville F. Caractéristiques IRM des neuromyélites optiques associées aux anticorps anti-MOG. J Neuroradiol 2018. [DOI: 10.1016/j.neurad.2018.01.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Labauge P. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? No. Rev Neurol (Paris) 2017; 173:614-615. [PMID: 29102328 DOI: 10.1016/j.neurol.2017.05.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2016] [Revised: 05/12/2017] [Accepted: 05/23/2017] [Indexed: 10/18/2022]
Affiliation(s)
- P Labauge
- CRC SEP, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 5, France.
| |
Collapse
|
19
|
Campello C, Parker F, Slimani S, Le Floch A, Herbrecht A, Aghakhani N, Lacroix C, Loiseau H, Lejeune J, Perrin G, Honnorat J, Dufour H, Chinot O, Figarella D, Bauchet L, Duffau H, Lonjon M, Labauge P, Messerer M, Daures J, Fabbro P, Ducot B. Tumeurs gliales intramédullaires de l’adulte : la série du rapport. Neurochirurgie 2017; 63:381-390. [DOI: 10.1016/j.neuchi.2016.10.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2016] [Revised: 09/18/2016] [Accepted: 10/23/2016] [Indexed: 10/19/2022]
|
20
|
Dunet V, Deverdun J, Charroud C, Le Bars E, Molino F, Menjot de Champfleur S, Maury F, Charif M, Ayrignac X, Labauge P, Castelnovo G, Pinna F, Bonafe A, Geny C, Menjot de Champfleur N. Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism. AJNR Am J Neuroradiol 2016; 37:2310-2316. [PMID: 27418471 DOI: 10.3174/ajnr.a4889] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Accepted: 06/05/2016] [Indexed: 01/14/2023]
Abstract
BACKGROUND AND PURPOSE Patients with vascular parkinsonism have higher cognitive decline and more basal ganglia lesions. We aimed to evaluate the relationship of cognitive impairment with functional connectivity between the basal ganglia and cingulate cortex in vascular parkinsonism. MATERIALS AND METHODS Thirty patients (8 with vascular parkinsonism and 22 with Parkinson disease) and 23 controls were enrolled. The Mattis Dementia Rating Scale and the Stroop Task were used to assess cognitive decline. MR imaging examinations included T1-MPRAGE, FLAIR, and resting-state fMRI sequences. MPRAGE was segmented to obtain basal ganglia and cingulate cortex volumes. FLAIR was segmented to obtain white matter hyperintensity lesion volume. Resting-state fMRI sequences were used to compare basal ganglia functional connectivity with the cingulate cortex between patients and controls. RESULTS Patients with vascular parkinsonism exhibited impaired attention, resistance to interference, and inhibitory control and an increased number of errors on the Stroop Task. They also had higher caudate nucleus and white matter hyperintensity lesion volumes, which were positively correlated (ρ = 0.75, P < .0001). Caudate nucleus functional connectivity with the perigenual anterior cingulate cortex was increased in patients with vascular parkinsonism compared with controls and patients with Parkinson disease, and it was positively correlated with the caudate nucleus volume (ρ = 0.44, P = .016). Caudate nucleus functional connectivity with the posterior cingulate cortex was decreased in patients with vascular parkinsonism compared with controls and negatively correlated with the number of errors on the Stroop test (ρ = -0.51, P = .0003). CONCLUSIONS In patients with vascular parkinsonism, cognitive decline could be related to changes of caudate nucleus functional connectivity with the cingulate cortex at resting-state, which may be induced by ischemia-related remodelling.
Collapse
Affiliation(s)
- V Dunet
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Department of Diagnostic and Interventional Radiology (V.D), Lausanne University Hospital, Lausanne, Switzerland
| | - J Deverdun
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Laboratoire Charles Coulomb (J.D., F.Molino), Centre National de la Recherche Scientifique Unite Mixte de Recherche 5221, Montpellier University, Montpellier, France
- Intrasense (J.D.), Montpellier, France
| | - C Charroud
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Neuropsychiatry: Epidemiological and Clinical Research (C.C.), Institut National de la Santé et de la Recherche Médicale, U1061, Montpellier University, La Colombiere Hospital, Montpellier, France
- Institut National de la Santé et de la Recherche Médicale (C.C.), U1198, Montpellier University, Montpellier, France
| | - E Le Bars
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
| | - F Molino
- Laboratoire Charles Coulomb (J.D., F.Molino), Centre National de la Recherche Scientifique Unite Mixte de Recherche 5221, Montpellier University, Montpellier, France
- Institut de Genomique Fonctionnelle (F.Molino), UMR 5203, Institut National de la Santé et de la Recherche Médicale, U661, Montpellier University, Montpellier, France
| | | | - F Maury
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
| | - M Charif
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
| | - X Ayrignac
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
| | - P Labauge
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
| | | | - F Pinna
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
| | - A Bonafe
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Team "Plasticity of Central Nervous System, Stem Cells and Glial Tumors" (A.B., N.M.d.C,), U1051, Institut of Neurosciences of Montpellier, Saint Eloi Hospital, Montpellier, France
| | - C Geny
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
- EuroMov (C.G.), Montpellier, France
- Movement to Health (C.G.), Montpellier University, Montpellier, France
| | - N Menjot de Champfleur
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Medical Imaging (N.M.d.C.), Caremeau University Hospital Center, Nimes, France
- Team "Plasticity of Central Nervous System, Stem Cells and Glial Tumors" (A.B., N.M.d.C,), U1051, Institut of Neurosciences of Montpellier, Saint Eloi Hospital, Montpellier, France
| |
Collapse
|
21
|
Danière F, Arquizan C, Gascou G, Costalat V, Labauge P, Bonafé A, Menjot de Champfleur N. Heamorrhagic cerebral metastasis and cerebral cavernous malformations: A misleading MRI pattern. J Neuroradiol 2016; 43:230-2. [DOI: 10.1016/j.neurad.2015.11.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Revised: 11/22/2015] [Accepted: 11/23/2015] [Indexed: 11/15/2022]
|
22
|
Davion JB, Cambron M, Duhin E, Chouraki A, Lacour A, Labauge P, Carra C, Ayrignac X, Vermersch P. Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal. J Neurol 2016; 263:1361-3. [PMID: 27159986 DOI: 10.1007/s00415-016-8144-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2016] [Revised: 04/24/2016] [Accepted: 04/25/2016] [Indexed: 11/26/2022]
Abstract
We report two cases of primary progressive multiple sclerosis (PPMS) included in the INFORMS cohort, experiencing a relapse related to a single MRI gadolinium-enhancing lesion 3 months after fingolimod withdrawal. These two patients share similarities with relapsing-remitting multiple sclerosis cases described in the same situation, suggesting that the initiating process of the active demyelinating plaques is also present in PPMS, even without relapses, but may be triggered as fingolimod is withdrawn. Although the results of the INFORMS study suggest that fingolimod may not slow down the progression, some PPMS patients might still benefit from a disease-modifying treatment.
Collapse
Affiliation(s)
- Jean-Baptiste Davion
- Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France.
| | - M Cambron
- Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France
- Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium
| | - E Duhin
- Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France
| | - A Chouraki
- Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France
| | - A Lacour
- Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France
| | - P Labauge
- Department of Neurology, University of Montpellier, Montpellier, France
| | - C Carra
- Department of Neurology, University of Montpellier, Montpellier, France
| | - X Ayrignac
- Department of Neurology, University of Montpellier, Montpellier, France
| | - P Vermersch
- Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France
| |
Collapse
|
23
|
Flaire A, Carra-Dalliere C, Ayrignac X, Blanc P, Labauge P. Glatiramer acetate-induced hepatitis in a patient with multiple sclerosis. Acta Neurol Belg 2016; 116:99-100. [PMID: 26141739 DOI: 10.1007/s13760-015-0506-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 06/24/2015] [Indexed: 11/25/2022]
Affiliation(s)
- A Flaire
- Department of Neurology, CHU Montpellier, 80, Avenue Augustin Fliche, 34295, Montpellier, France
| | - Clarisse Carra-Dalliere
- Department of Neurology, CHU Montpellier, 80, Avenue Augustin Fliche, 34295, Montpellier, France.
| | - X Ayrignac
- Department of Neurology, CHU Montpellier, 80, Avenue Augustin Fliche, 34295, Montpellier, France
| | - P Blanc
- Department of Hepatogastroenterology, CHU Montpellier, Montpellier, France
| | - P Labauge
- Department of Neurology, CHU Montpellier, 80, Avenue Augustin Fliche, 34295, Montpellier, France
| |
Collapse
|
24
|
Labauge P, Carra-Dalliere C, Ayrignac X, Menjot de Champfleur N. Low Signals on T2* and SWI Sequences in Patients with MS with Progressive Multifocal Leukoencephalopathy. AJNR Am J Neuroradiol 2016; 37:E11. [PMID: 26635282 DOI: 10.3174/ajnr.a4632] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | | | - N Menjot de Champfleur
- Department Neuroradiology Montpellier University Hospital Centre Hospitalo-Universitair Gui de Chauliac Montpellier, France
| |
Collapse
|
25
|
Labauge P, Ayrignac X, Carra-Dallière C, Menjot de Champfleur N. Leucodistrofie dell’adulto. Neurologia 2016. [DOI: 10.1016/s1634-7072(15)76144-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
26
|
Ayrignac X, Menjot de Champfleur N, Menjot de Champfleur S, Carra-Dallière C, Deverdun J, Corlobe A, Labauge P. Brain magnetic resonance imaging helps to differentiate atypical multiple sclerosis with cavitary lesions and vanishing white matter disease. Eur J Neurol 2016; 23:995-1000. [DOI: 10.1111/ene.12931] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Accepted: 11/04/2015] [Indexed: 02/01/2023]
Affiliation(s)
- X. Ayrignac
- Department of Neurology; Montpellier University Hospital; Gui de Chauliac Hospital; Montpellier France
- Neuroscience Institute of Montpellier (INM); Inserm UMR1051; Saint-Eloi Hospital; Montpellier France
| | - N. Menjot de Champfleur
- Department of Neuroradiology; Montpellier University Hospital; Gui de Chauliac Hospital; Montpellier France
- I2FH; Institut d'Imagerie Fonctionnelle Humaine; Montpellier University Hospital; Montpellier France
| | - S. Menjot de Champfleur
- Department of Neuroradiology; Montpellier University Hospital; Gui de Chauliac Hospital; Montpellier France
- I2FH; Institut d'Imagerie Fonctionnelle Humaine; Montpellier University Hospital; Montpellier France
| | - C. Carra-Dallière
- Department of Neurology; Montpellier University Hospital; Gui de Chauliac Hospital; Montpellier France
| | - J. Deverdun
- Department of Neuroradiology; Montpellier University Hospital; Gui de Chauliac Hospital; Montpellier France
- I2FH; Institut d'Imagerie Fonctionnelle Humaine; Montpellier University Hospital; Montpellier France
| | - A. Corlobe
- Department of Neurology; Nimes University Hospital; Gui de Chauliac Hospital; Montpellier France
| | - P. Labauge
- Department of Neurology; Montpellier University Hospital; Gui de Chauliac Hospital; Montpellier France
| |
Collapse
|
27
|
Bousquet J, Bourret R, Camuzat T, Augé P, Domy P, Bringer J, Best N, Jonquet O, de la Coussaye JE, Noguès M, Robine JM, Avignon A, Blain H, Combe B, Dray G, Dufour V, Fouletier M, Giraudeau N, Hève D, Jeandel C, Laffont I, Larrey D, Laune D, Laurent C, Mares P, Marion C, Pastor E, Pélissier JY, Radier-Pontal F, Reynes J, Royère E, Ychou M, Bedbrook A, Granier S, Abecassis F, Albert S, Adnet PA, Alomène B, Amouyal M, Arnavielhe S, Asteriou T, Attalin V, Aubas P, Azevedo C, Badin M, Bakhti, Baptista G, Bardy B, Battesti MP, Bénézet O, Bernard PL, Berr C, Berthe J, Bobia X, Bockaert J, Boegner C, Boichot S, Bonnin HY, Boulet P, Bouly S, Boubakri C, Bourdin A, Bourrain JL, Bourrel G, Bouix V, Breuker C, Bruguière V, Burille J, Cade S, Caimmi D, Calmels MV, Camu W, Canovas G, Carre V, Cavalli G, Cayla G, Chiron R, Claret PG, Coignard P, Coroian F, Costa DJ, Costa P, Cottalorda, Coulet B, Coupet AL, Courrouy-Michel MC, Courtet P, Cristol JP, Cros V, Cuisinier F, Daien C, Danko M, Dauenhauer P, Dauzat M, David M, Davy JM, Delignières D, Demoly P, Desplan J, Dhivert-Donnadieu H, Dujols P, Dupeyron A, Dupeyron G, Engberink O, Enjalbert M, Fattal C, Fernandes J, Fesler P, Fraisse P, Froger J, Gabrion P, Galano E, Gellerat-Rogier M, Gellis A, Goucham AY, Gouzi F, Gressard F, Gris JC, Guillot B, Guiraud D, Handweiler V, Hantkié H, Hayot M, Hérisson C, Heroum C, Hoa D, Jacquemin S, Jaber S, Jakovenko D, Jorgensen C, Journot L, Kaczorek M, Kouyoudjian P, Labauge P, Landreau L, Lapierre M, Leblond C, Léglise MS, Lemaitre JM, Le Moing V, Le Quellec A, Leclercq F, Lehmann S, Lognos B, Lussert JM, Makinson A, Mandrick K, Marmelat V, Martin-Gousset P, Matheron A, Mathieu G, Meissonnier M, Mercier G, Messner P, Meunier C, Mondain M, Morales R, Morel J, Morquin D, Mottet D, Nérin P, Nicolas P, Ninot G, Nouvel F, Ortiz JP, Paccard D, Pandraud G, Pasdelou MP, Pasquié JL, Patte K, Perrey S, Pers YM, Picot MC, Pin JP, Pinto N, Porte E, Portejoie F, Pujol JL, Quantin X, Quéré I, Raffort N, Ramdani S, Ribstein J, Rédini-Martinez I, Richard S, Ritchie K, Riso JP, Rivier F, Rolland C, Roubille F, Sablot D, Savy JL, Schifano L, Senesse P, Sicard R, Soua B, Stephan Y, Strubel D, Sultan A, Taddei-Ologeanu, Tallon G, Tanfin M, Tassery H, Tavares I, Torre K, Touchon J, Tribout V, Uziel A, Van de Perre P, Vasquez X, Verdier JM, Vergne-Richard C, Vergotte G, Vian L, Viarouge-Reunier C, Vialla F, Viart F, Villain M, Villiet M, Viollet E, Wojtusciszyn A, Aoustin M, Bourquin C, Mercier J. Introduction. Presse Med 2015; 44 Suppl 1:S1-5. [DOI: 10.1016/j.lpm.2015.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
28
|
Carra-Dalliere C, Menjot de Champfleur N, Deverdun J, Ayrignac X, Nerrant E, Makinson A, Casanova ML, Labauge P. Use of quantitative susceptibility mapping (QSM) in progressive multifocal leukoencephalopathy. J Neuroradiol 2015; 43:6-10. [PMID: 26475668 DOI: 10.1016/j.neurad.2015.08.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2015] [Revised: 08/01/2015] [Accepted: 08/14/2015] [Indexed: 10/22/2022]
Abstract
BACKGROUND Progressive multifocal leukoencephalopathy (PML) is an opportunistic demyelinating encephalopathy related to JC virus. Its characteristics on conventional brain MRI are well known and are important for the diagnosis. OBJECTIVE To analyze SWI hypointensities recently described in U-fibers and cortex adjacent to the white matter lesions of PML. METHODS Prospective study including four patients with an history of definite diagnosis of PML. Clinical data were collected retrospectively. Brain MRI exams were done on a 3T magnet, including FLAIR, T2 GRE sequences and SWI. RESULTS Four males were included (mean age: 47 years, mean PML duration: 24.2 months). Immunosuppression was related to AIDS (n=2), natalizumab for multiple sclerosis (n=1), B-cell lymphoma treated by chemotherapeutic agents and rituximab (n=1). All patients had SWI hypointensities in cortex and/or U-fibers adjacent to the white matter lesions. QSM always suggested a paramagnetic effect. CONCLUSION SWI and T2 GRE hypointensities in cortex and U-fibers adjacent to the white matter lesions seem highly prevalent in PML, irrespective of the delay between PML onset and the MRI. QSM data suggest a paramagnetic effect.
Collapse
Affiliation(s)
- C Carra-Dalliere
- Department of Neurology, Montpellier University Hospital, Gui-de-Chauliac Hospital, 34295 Montpellier, France.
| | - N Menjot de Champfleur
- Department of Neuroradiology, Montpellier University Hospital, Gui-de-Chauliac Hospital, 34295 Montpellier, France; Institut d'imagerie fonctionnelle humaine (I2FH), Montpellier University Hospital, 34295 Montpellier, France
| | - J Deverdun
- Department of Neuroradiology, Montpellier University Hospital, Gui-de-Chauliac Hospital, 34295 Montpellier, France; Institut d'imagerie fonctionnelle humaine (I2FH), Montpellier University Hospital, 34295 Montpellier, France
| | - X Ayrignac
- Department of Neurology, Montpellier University Hospital, Gui-de-Chauliac Hospital, 34295 Montpellier, France
| | - E Nerrant
- Department of Neurology, Montpellier University Hospital, Gui-de-Chauliac Hospital, 34295 Montpellier, France
| | - A Makinson
- Department of Infectious Diseases, Montpellier University Hospital, Saint-Éloi Hospital, 34295 Montpellier, France
| | - M L Casanova
- Department of Infectious Diseases, Montpellier University Hospital, Saint-Éloi Hospital, 34295 Montpellier, France
| | - P Labauge
- Department of Neurology, Montpellier University Hospital, Gui-de-Chauliac Hospital, 34295 Montpellier, France
| |
Collapse
|
29
|
Laffont I, Jourdan C, Coroian F, Blain H, Carre V, Viollet E, Tavares I, Fattal C, Gelis A, Nouvel F, Bakhti K, Cros V, Patte K, Schifano L, Porte M, Galano E, Dray G, Fouletier M, Rivier F, Morales R, Labauge P, Camu W, Combe B, Morel J, Froger J, Coulet B, Cottalorda J, Kouyoumdjian P, Jonquet O, Landreau L, Bonnin HY, Hantkié O, Nicolas P, Enjalbert M, Leblond C, Soua B, Coignard P, Guiraud D, Azevedo C, Mottet D, Fraisse P, Pastor E, Mercier J, Bourret R, Bousquet J, Pélissier J, Bardy B, Herisson C, Dupeyron A. [Living Lab MACVIA. Disability]. Presse Med 2015; 44 Suppl 1:S60-9. [PMID: 26482491 DOI: 10.1016/j.lpm.2015.07.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Affiliation(s)
- I Laffont
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France; Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France.
| | - C Jourdan
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France
| | - F Coroian
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France; Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - H Blain
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHRU de Montpellier, département de gériatrie, 34090 Montpellier, France
| | - V Carre
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France
| | - E Viollet
- CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France; CHU Carémeau, CEDMH, 30029 Nîmes, France
| | - I Tavares
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France
| | - C Fattal
- Association APPROCHE, CMRRF de Kerpape, BP 78, 56275 Ploemeur cedex, France
| | - A Gelis
- Centre Mutualiste Propara, 34000 Montpellier, France
| | - F Nouvel
- CHU Carémeau, CEDMH, 30029 Nîmes, France
| | - K Bakhti
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France; Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - V Cros
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France
| | - K Patte
- Institut Marin Saint-Pierre, 34250 Palavas les Flots, France
| | - L Schifano
- Institut Marin Saint-Pierre, 34250 Palavas les Flots, France
| | - M Porte
- CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - E Galano
- CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - G Dray
- École des Mines d'Alès, 30100 Alès, France
| | | | - F Rivier
- CHU de Montpellier, centre de référence Grand Sud des maladies neuromusculaires, département de neuropédiatrie, 34090 Montpellier, France
| | - R Morales
- CHRU de Montpellier, département de neurologie, 34090 Montpellier, France
| | - P Labauge
- CHRU de Montpellier, département de neurologie, 34090 Montpellier, France
| | - W Camu
- CHRU de Montpellier, département de neurologie, 34090 Montpellier, France
| | - B Combe
- CHRU de Montpellier, département de rhumatologie, 34090 Montpellier, France
| | - J Morel
- CHRU de Montpellier, département de rhumatologie, 34090 Montpellier, France
| | - J Froger
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - B Coulet
- CHRU de Montpellier, département de chirurgie orthopédique, 34090 Montpellier, France
| | - J Cottalorda
- CHRU de Montpellier, département de chirurgie orthopédique et plastique infantile, 34090 Montpellier, France
| | - P Kouyoumdjian
- CHU Carémeau, département de chirurgie orthopédique, 30029 Nîmes, France
| | - O Jonquet
- CHRU de Montpellier, département de réanimation, 34090 Montpellier, France
| | - L Landreau
- CHRU de Montpellier, département de réanimation, 34090 Montpellier, France
| | - H-Y Bonnin
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - O Hantkié
- Centre Bourgès, groupe Oc Santé, 34173 Castelneau-le-lez cedex, France
| | - P Nicolas
- Centre Bourgès, groupe Oc Santé, 34173 Castelneau-le-lez cedex, France
| | - M Enjalbert
- Centre Bouffard-Vercelli, 66290 Cerbère, France; Association APPROCHE, CMRRF de Kerpape, BP 78, 56275 Ploemeur cedex, France
| | - C Leblond
- Centre Bouffard-Vercelli, 66290 Cerbère, France
| | - B Soua
- Association ADAGES, Les Fontaines d'Ô, 34000 Montpellier, France
| | - P Coignard
- Association APPROCHE, CMRRF de Kerpape, BP 78, 56275 Ploemeur cedex, France
| | - D Guiraud
- Université de Montpellier, laboratoire d'informatique, de robotique et de microélectronique de Montpellier, 34090 Montpellier, France; Institut national de recherche en informatique et en automatique, LIRMM, université de Montpellier, 34090 Montpellier, France
| | - C Azevedo
- Université de Montpellier, laboratoire d'informatique, de robotique et de microélectronique de Montpellier, 34090 Montpellier, France; Institut national de recherche en informatique et en automatique, LIRMM, université de Montpellier, 34090 Montpellier, France
| | - D Mottet
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - P Fraisse
- Université de Montpellier, laboratoire d'informatique, de robotique et de microélectronique de Montpellier, 34090 Montpellier, France
| | - E Pastor
- CCAS de Lattes, 34970 Lattes, France
| | - J Mercier
- CHRU de Montpellier, U1046 Inserm, université Montpellier 1, 34090 Montpellier, France
| | - R Bourret
- CHRU de Montpellier, Direction générale, 34090 Montpellier, France
| | | | - J Pélissier
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France
| | - B Bardy
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - C Herisson
- CHRU de Montpellier, département de médecine physique et de réadaptation, 34090 Montpellier, France; Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France
| | - A Dupeyron
- Movement to Health (M2H), Euromov, université de Montpellier, Montpellier, France; CHU de Nîmes, hôpital Carémeau et du Grau du Roi, département de médecine physique et de réadaptation, 30029 Nîmes, France; CHU Carémeau, CEDMH, 30029 Nîmes, France
| |
Collapse
|
30
|
Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler 2015; 22:955-9. [DOI: 10.1177/1352458515602337] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Accepted: 08/02/2015] [Indexed: 11/17/2022]
Abstract
Background: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. Objective: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. Methods: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. Results: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 ( p<0.001) and median EDSS from 5 to 3 ( p=0.02). Body mass index (BMI) was predictive of EDSS worsening. Conclusions: RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.
Collapse
Affiliation(s)
- N Collongues
- Department of Neurology, Hopital de Hautepierre, France
| | - D Brassat
- Department of Neurology, Hopital Purpan, France
| | - E Maillart
- Department of Neurology, Hopital Pitie-Salpetriere, France
| | - P Labauge
- Department of Neurology, Hopital Universitaire de Montpellier, France
| | - JC Ouallet
- Department of Neurology, Centre Hospitalier Universitaire de Bordeaux, France
| | - C Carra-Dalliere
- Department of Neurology, Hopital Universitaire de Montpellier, France
| | - T Moreau
- Department of Neurology, Hopital Universitaire de Dijon, France
| | - B Bourre
- Department of Neurology, Hopital Charles Nicolle, France
| | - C Papeix
- Department of Neurology, Hopital Pitie-Salpetriere, France
| | - B Brochet
- Department of Neurology, Centre Hospitalier Universitaire de Bordeaux, France
| | - B Audoin
- Department of Neurology, Hopital Universitaire de Marseille, France
| | - S Vukusic
- Department of neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
| | - J de Seze
- Department of Neurology, Hopital de Hautepierre, France
| | - R Marignier
- Department of neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
| | | |
Collapse
|
31
|
Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. J Neurol 2015; 262:1637-45. [DOI: 10.1007/s00415-015-7758-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Revised: 04/17/2015] [Accepted: 04/20/2015] [Indexed: 12/31/2022]
|
32
|
Carra-Dalliere C, Menjot de Champfleur N, Ayrignac X, Deverdun J, Labauge P. Quantitative susceptibility mapping suggests a paramagnetic effect in PML. Neurology 2015; 84:1501-2. [DOI: 10.1212/wnl.0000000000001455] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
33
|
Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G, Brassat D, Loussouarn D, Salou M, Laplaud D, Casez O, Bockaert J, Marin P, Thouvenot E. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler 2015; 21:1251-61. [DOI: 10.1177/1352458514561906] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2014] [Accepted: 11/05/2014] [Indexed: 01/15/2023]
Abstract
Background: Despite sensitivity of MRI to diagnose multiple sclerosis (MS), prognostic biomarkers are still needed for optimized treatment. Objective: The objective of this paper is to identify cerebrospinal fluid (CSF) diagnostic biomarkers of MS using quantitative proteomics and to analyze their expression at different disease stages. Methods: We conducted differential analysis of the CSF proteome from control and relapsing–remitting MS (RRMS) patients followed by verification by ELISA of candidate biomarkers in CSF and serum in control, clinically isolated syndrome (CIS), RRMS and progressive MS (PMS) patients. Results: Twenty-two of the 527 quantified proteins exhibited different abundances in control and RRMS CSF. These include chitinase 3-like protein 1 (CHI3L1) and 2 (CHI3L2), which showed a strong expression in brain of MS patients, especially in astrocytes and microglial cells from white matter plaques. CSF and serum CHI3L1 levels increased with the disease stage and CIS patients with high CSF (>189 ng/ml) and serum (>33 ng/ml) CHI3L1 converted more rapidly to RRMS (log rank test, p < 0.05 and p < 0.001, respectively). In contrast, CSF CHI3L2 levels were lower in PMS than in RRMS patients. Accordingly, CSF CHI3L1/CHI3L2 ratio accurately discriminated PMS from RRMS. Conclusions: CSF CHI3L1 and CHI3L2 and serum CHI3L1 might help to define MS disease stage and have a prognostic value in CIS.
Collapse
Affiliation(s)
- G Hinsinger
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - N Galéotti
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - N Nabholz
- Service d’Ophtalmologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - S Urbach
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - V Rigau
- Service d’Anatomopathologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - C Demattei
- Département d’Information Médicale, CHU de Nîmes, France
| | - S Lehmann
- Service de Biochimie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - W Camu
- Service de Neurologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - P Labauge
- Service de Neurologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - G Castelnovo
- Service de Neurologie, Hôpital Carémeau, CHU de Nîmes, France
| | - D Brassat
- Service de Neurologie, Hôpital Purpan, CHU de Toulouse, France
| | - D Loussouarn
- Service d’Anatomopathologie, CHU de Nantes, France
| | | | - D Laplaud
- INSERM 1064, France/Service de Neurologie, CHU de Nantes, France
| | - O Casez
- Service de Neurologie, CHU de Grenoble, France
| | - J Bockaert
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - P Marin
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - E Thouvenot
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France/Service de Neurologie, Hôpital Carémeau, CHU de Nîmes, France
| |
Collapse
|
34
|
Corlobé A, Taithe F, Clavelou P, Pierre E, Carra-Dallière C, Ayrignac X, Mouzat K, Lumbroso S, Menjot de Champfleur N, Koenig M, Boespflug-Tanguy O, Labauge P. A novel autosomal dominant leukodystrophy with specific MRI pattern. J Neurol 2015; 262:988-91. [PMID: 25683759 DOI: 10.1007/s00415-015-7660-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 01/28/2015] [Accepted: 01/29/2015] [Indexed: 01/15/2023]
Abstract
Etiologic diagnosis of adulthood leukodystrophy is challenging in neurologic practice. We describe here the clinico-radiological features of a novel autosomal dominant leukodystrophy in a single family. Clinical and MRI features were recorded in a three generation family. Exome sequencing was performed in two affected relatives and one healthy member. Four total relatives (3 women and 1 man, mean age at onset: 45, range 32-59) were followed: 2 for migraine and 2 for cognitive loss. MRI features were homogeneous in the four affected relatives: extensive and symmetrical white matter hyperintensities on T2-weighted images, with a posterior predominance, involvement of the middle cerebellar peduncles, corpus callosum and the posterior limb of the internal capsules. An extensive metabolic screening was negative. In addition, sequencing of pathogenic genes involved in dominant leukodystrophies (NOTCH3, LMNB1, GFAP, CSF1R) was negative. No mutation has been identified yet with exome sequencing. This report is peculiar because of dominant inheritance, adult onset, highly homogeneous white matter hyperintensities on T2-weighted MR images, predominant in the middle cerebellar peduncles and posterior part of internal capsule and absence of mutation of the genes involved in dominant leukodystrophies.
Collapse
Affiliation(s)
- A Corlobé
- Department of Neurology, CHU Gui de Chauliac, CHU Montpellier, 80 avenue Augustin Fliche, 34295, Montpellier Cedex 5, France,
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Renard D, Mine M, Pipiras E, Labauge P, Delahaye A, Benzacken B, Tournier-Lasserve E. Cerebral small-vessel disease associated with COL4A1 and COL4A2 gene duplications. Neurology 2014; 83:1029-31. [DOI: 10.1212/wnl.0000000000000769] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
36
|
Torre A, Paillusson B, Fain V, Labauge P, Pelage JP, Fauconnier A. Reply: Uterine artery embolization for severe symptomatic fibroids: effects on fertility and symptoms. Hum Reprod 2014; 29:1833-4. [DOI: 10.1093/humrep/deu148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Lionnet C, Carra C, Ayrignac X, Levade T, Gayraud D, Castelnovo G, Besson G, Androdias G, Vukusic S, Confavreux C, Zaenker C, De Seze J, Collongues N, Blanc F, Tranchant C, Wallon D, Hannequin D, Gerdelat-Mas A, Brassat D, Clanet M, Zephir H, Outteryck O, Vermersch P, Labauge P. [Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects]. Rev Neurol (Paris) 2014; 170:445-53. [PMID: 24746394 DOI: 10.1016/j.neurol.2014.01.675] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2013] [Revised: 01/13/2014] [Accepted: 01/16/2014] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Cerebrotendinous xanthomatosis, a metabolic leukodystrophy with an autosomal recessive inheritance, is secondary to deficiency of sterol 27-hydroxylase, an enzyme involved in cholesterol catabolism. Classical symptoms include clinical or infraclinical xanthomas affecting the skin and tendons, early cataracts, neurological signs and diarrhea. Brain imaging reveals involvement of the dentate nuclei and periventricular white matter hyperintensities. The diagnosis is based on an increased cholestanol level in serum, confirmed by the presence of a mutation in the CYP27A1 gene. Treatment is based on chenodeoxycholic acid. METHOD We report a retrospective multicentric study of 15 cases of cerebrotendinous xanthomatosis diagnosed in French adults. Clinical, molecular and MRI findings were recorded in all patients. RESULTS The average age at diagnosis was 39years (range 27-65). Disease onset occurred in childhood in 73% of patients and in adulthood in 27%. All patients with a pediatric onset were diagnosed during adulthood (age range 28-65years). Clinical symptoms variably associated cerebellar syndrome, pyramidal syndrome, cognitive decline, epilepsy, neuropathy (sought in 10 of our patients, present in forms in 8), psychiatric disorders, cataract and xanthomas. One patient had an atypical presentation: monoparesis associated with xanthomas. Brain MRI was abnormal in all: findings consisted in T2-weighted hyperintensity of the dentate nuclei (47%), periventricular leuoencephalopathy (73%) which preferentially involved the posterior cerebral part (60%), leucoencephalopathy with a vascular pattern (7%), hyperintensity of the cortico-spinal tracts (53%), globi pallidi, corpus callosum and cerebral atrophy (33%). Serum cholestanol was elevated in 93% of patients. The most frequent mutation was 1183C>T (n=5/15). Under treatment with chenodeoxycholic acid, eight patients improved initially, followed by stabilization in five of them, and worsening in the others. Four patients died. CONCLUSION Patients with the xanthoma-neurological disorder association should be tested for cerebrotendinous xanthomatosis. The disease often begins in childhood with a diagnostic delay but also in adulthood. Involvement of the dentate nuclei is specific but not sensitive and the supratentorial leucoencephalopathy is not specific but with an antero-posterior gradient. A vascular distribution and involvement of the corpus callosum are possible. Serum cholestanol assay is very reliable: an elevated level provides the diagnosis, which must nevertheless be confirmed by molecular biology.
Collapse
Affiliation(s)
- C Lionnet
- Service de neurologie, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - C Carra
- Service de neurologie, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - X Ayrignac
- Service de neurologie, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - T Levade
- Laboratoire de biochimie, hôpital Rangueil, CHU de Toulouse, 1, avenue J.-Poulhès, 31403 Toulouse, France
| | - D Gayraud
- Service de neurologie, centre hospitalier du pays d'Aix, avenue des Tamaris, 13616 Aix-en-Provence cedex 1, France
| | - G Castelnovo
- Service de neurologie, hôpital Caremeau, CHU de Nîmes, place du Professeur-Debré, 30029 Nîmes cedex 4, France
| | - G Besson
- Service de neurologie, CHU de Grenoble, boulevard de la Chantourne, 38700 La Tronche, France
| | - G Androdias
- Service de neurologie, hôpital Pierre-Wertheimer, CHU de Lyon, 59, boulevard Pinel, 69500 Bron, France
| | - S Vukusic
- Service de neurologie, hôpital Pierre-Wertheimer, CHU de Lyon, 59, boulevard Pinel, 69500 Bron, France
| | - C Confavreux
- Service de neurologie, hôpital Pierre-Wertheimer, CHU de Lyon, 59, boulevard Pinel, 69500 Bron, France
| | - C Zaenker
- Cabinet privé, 64, rue Robert-Schuman, 68000 Colmar, France
| | - J De Seze
- Service de neurologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France
| | - N Collongues
- Service de neurologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France
| | - F Blanc
- Service de neurologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France
| | - C Tranchant
- Service de neurologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France
| | - D Wallon
- Service de neurologie, CHU de Rouen, 1, rue Germont, 70031 Rouen, France
| | - D Hannequin
- Service de neurologie, CHU de Rouen, 1, rue Germont, 70031 Rouen, France
| | - A Gerdelat-Mas
- Service de neurologie, hôpital Purpan, CHU de Toulouse, place du Docteur-Baylac, 31059 Toulouse cedex 9, France
| | - D Brassat
- Service de neurologie, hôpital Purpan, CHU de Toulouse, place du Docteur-Baylac, 31059 Toulouse cedex 9, France
| | - M Clanet
- Service de neurologie, hôpital Purpan, CHU de Toulouse, place du Docteur-Baylac, 31059 Toulouse cedex 9, France
| | - H Zephir
- Service de neurologie D, hôpital Roger-Salengro, CHU de Lille, avenue du Pr-Émile-Laine, 59037 Lille cedex, France
| | - O Outteryck
- Service de neurologie D, hôpital Roger-Salengro, CHU de Lille, avenue du Pr-Émile-Laine, 59037 Lille cedex, France
| | - P Vermersch
- Service de neurologie D, hôpital Roger-Salengro, CHU de Lille, avenue du Pr-Émile-Laine, 59037 Lille cedex, France
| | - P Labauge
- Service de neurologie, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France.
| |
Collapse
|
38
|
Marelli C, Salih MM, Nguyen K, Mallaret M, Drouot N, Labauge P, Koenig M. Paraparésie spastique héréditaire à phénotype complexe avec mutation dans le gène FA2H : description de 5 cas. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Nerrant E, Charif M, Ramay AS, Perrochia H, Patrier L, Menjot De Champfleur N, Labauge P. Une complication rénale rare du traitement par interféron-β (IFN-b) dans la sclérose en plaques : le syndrome hémolytique et urémique. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou PY, Nicolino M, Simon A, Viallard JF, Costedoat-Chalumeau N, Courcoux MF, Pondarré C, Hilliquin P, Chatelus E, Foltz V, Guillaume S, Rossignol M, Abenhaim L. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014; 275:398-408. [PMID: 24206418 DOI: 10.1111/joim.12155] [Citation(s) in RCA: 106] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
OBJECTIVES The aim of this study was to investigate whether the quadrivalent human papillomavirus (HPV) vaccine Gardasil is associated with a change in the risk of autoimmune disorders (ADs) in young female subjects. DESIGN Systematic case-control study of incident ADs associated with quadrivalent HPV vaccination in young women across France. PARTICIPANTS AND SETTING A total of 113 specialised centres recruited (from December 2007 to April 2011) females aged 14-26 years with incident cases of six types of ADs: idiopathic thrombocytopenic purpura (ITP), central demyelination/multiple sclerosis (MS), Guillain-Barré syndrome, connective tissue disorders (systemic lupus erythematosus, rheumatoid arthritis/juvenile arthritis), type 1 diabetes mellitus and autoimmune thyroiditis. Control subjects matched to cases were recruited from general practice. ANALYSIS Multivariate conditional logistic regression analysis; factors included age, geographical origin, smoking, alcohol consumption, use of oral contraceptive(s) or vaccine(s) other than Gardasil received within 24 months before the index date and personal/family history of ADs. RESULTS Overall, 211 definite cases of ADs were matched to 875 controls. The adjusted odds ratio (OR) for any quadrivalent HPV vaccine use was 0.9 [95% confidence interval (CI) 0.5-1.5]. The individual ORs were 1.0 (95% CI 0.4-2.6) for ITP, 0.3 (95% CI 0.1-0.9) for MS, 0.8 (95% CI 0.3-2.4) for connective disorders and 1.2 (95% CI 0.4-3.6) for type 1 diabetes. No exposure to HPV vaccine was observed in cases with either Guillain-Barré syndrome or thyroiditis. CONCLUSIONS No evidence of an increase in the risk of the studied ADs was observable following vaccination with Gardasil within the time periods studied. There was insufficient statistical power to allow conclusions to be drawn regarding individual ADs.
Collapse
Affiliation(s)
- L Grimaldi-Bensouda
- LA-SER, Paris, France; Conservatoire National des Arts et Métiers (CNAM), Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Nerrant E, Charif M, Castelnovo G, Salsac C, Eliaou JF, Labauge P, Vincent T. Les anticorps anti-KIR4.1 sont-ils des biomarqueurs de la sclérose en plaques ? Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Torre A, Paillusson B, Fain V, Labauge P, Pelage JP, Fauconnier A. Uterine artery embolization for severe symptomatic fibroids: effects on fertility and symptoms. Hum Reprod 2014; 29:490-501. [DOI: 10.1093/humrep/det459] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Cerutti D, Guilpain P, Schiffmann A, Rivière S, Carra C, Labauge P, Le Quellec A. [Serious clinical manifestations of vitamin deficiency after a "sleeve" gastrectomy: role of psychogenic anorexia]. Rev Med Interne 2013; 35:609-12. [PMID: 24321087 DOI: 10.1016/j.revmed.2013.11.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Revised: 10/05/2013] [Accepted: 11/01/2013] [Indexed: 01/07/2023]
Abstract
INTRODUCTION Morbid obesity is an emerging condition in the general population. Bariatric surgery, which has demonstrated its effectiveness for weight loss, mortality and morbidity related to obesity, is required in some patients. However, it may be associated with various adverse effects, including vitamin deficiencies. CASE REPORT We report a 33-year old man who presented central and peripheral neurological deficits and cardiac manifestations related to multiple vitamin deficiencies, following "sleeve" gastrectomy. The vitamin deficiencies were related to insufficient ingesta secondary to psychogenic anorexia. The patient improved with vitamins, antidepressant drugs and atypical neuroleptics. CONCLUSION Post-operative complications of "sleeve" gastrectomy include vitamin deficiencies that can develop in the context of psychogenic anorexia and ingesta reduction, in the absence of any digestive malabsorption.
Collapse
Affiliation(s)
- D Cerutti
- Département de médecine interne, équipe « médecine interne, maladies multi-organiques de l'adulte », université Montpellier 1, hôpital Saint-Éloi, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | - P Guilpain
- Département de médecine interne, équipe « médecine interne, maladies multi-organiques de l'adulte », université Montpellier 1, hôpital Saint-Éloi, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France.
| | - A Schiffmann
- Département de médecine interne, équipe « médecine interne, maladies multi-organiques de l'adulte », université Montpellier 1, hôpital Saint-Éloi, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | - S Rivière
- Département de médecine interne, équipe « médecine interne, maladies multi-organiques de l'adulte », université Montpellier 1, hôpital Saint-Éloi, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | - C Carra
- Département de neurologie, université Montpellier 1, hôpital Gui-De-Chauliac, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | - P Labauge
- Département de neurologie, université Montpellier 1, hôpital Gui-De-Chauliac, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | - A Le Quellec
- Département de médecine interne, équipe « médecine interne, maladies multi-organiques de l'adulte », université Montpellier 1, hôpital Saint-Éloi, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| |
Collapse
|
44
|
Corlobé A, Renard D, Goizet C, Berger E, Rumbach L, Robinson A, Dupuy D, Touzé E, Zéphir H, Vermersch P, Brochet B, Edan G, Deburghgraeve V, Créange A, Castelnovo G, Cohen M, Lebrun-Frenay C, Boespflug-Tanguy O, Labauge P. [Cavitary lesions in multiple sclerosis: multicenter study on twenty patients]. Rev Neurol (Paris) 2013; 169:965-9. [PMID: 24139243 DOI: 10.1016/j.neurol.2013.02.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2012] [Revised: 01/03/2013] [Accepted: 02/04/2013] [Indexed: 10/26/2022]
Abstract
INTRODUCTION Cavitary white matter changes are mainly described in leukodystrophies and especially in vanishing white matter disease. Large cavitary lesions are not typical for multiple sclerosis (MS). METHODS We studied MS patients with large cavitary brain lesions. Patient characteristics, disease onset/duration/subtype, expanded disability status scale (EDSS), mini mental state (MMS), vanishing white matter disease genetic analysis, and MRI characteristics of the cavitary lesions were analyzed. RESULTS Twenty patients were analyzed (6 men and 14 women). Mean age at disease onset was 37.6 (range 17-58). Mean disease duration was 10 years (range 2-20). Five patients had initial relapsing-remitting MS and nine patients had primary-progressive MS. Mean EDSS was 5.5 (range 2-8). Mean MMS was 20/30. Vanishing white matter disease genetic analysis was performed and negative in seven patients. Inferior corpus callosum lesions were seen in all patients with available sagittal FLAIR sequences. Cavitary lesions were strictly supratentorial, and located inside the diffuse leukoencephalopathy, with often a posterior predominance. CONCLUSION MS patients with large cavitary lesions seem to represent a MS subgroup, predominantly women, with relatively late disease onset, predominantly primary-progressive type, relatively high EDSS scores, and severe cognitive dysfunction.
Collapse
Affiliation(s)
- A Corlobé
- Service de neurologie, hôpital Gui-de-Chauliac, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Gronier S, Ayrignac X, Lamy C, Honnorat J, Thomas P, Lebrun-Frenay C, Labauge P. [Symptomatic giant Virchow-Robin spaces]. Rev Neurol (Paris) 2013; 169:898-902. [PMID: 24119855 DOI: 10.1016/j.neurol.2013.05.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2013] [Revised: 04/25/2013] [Accepted: 05/14/2013] [Indexed: 10/26/2022]
Abstract
INTRODUCTION Perivascular spaces, known as Virchow-Robin spaces (VRS), may become massively enlarged but are usually an incidental finding. However, a few reports on patients with unusually large VRS have mentioned association with neurological symptoms. We report a series of three symptomatic patients with extremely wide Virchow-Robin spaces documented on brain magnetic resonance imaging (MRI). METHODS We retrospectively analyzed the medical records and brain MRI of three symptomatic patients, who had been diagnosed with VRS widening. CASE REPORTS In all three patients, the unusual widening of the VRS was located within the subcortical white matter with asymmetric distribution. Their neurological symptoms were epilepsy and neurological deficits which correlated well with the lesions seen on the MRI. Two patients had associated white matter hyperintensities: in the first case associated gliosis and in the second case, with vascular leukoencephalopathy. CONCLUSIONS Enlarged symptomatic VRS are rare. The underlying pathophysiological mechanisms remain uncertain. We report three cases with symptomatic giant dilatation of the Virchow-Robin spaces.
Collapse
Affiliation(s)
- S Gronier
- Service de neurologie, pôle de neurosciences cliniques, CHU de Nice, hôpital Pasteur, 30, voie Romaine, 06002 Nice cedex 1, France
| | | | | | | | | | | | | |
Collapse
|
46
|
Outteryck O, Ongagna J, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet J, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol 2013; 21:40-8. [DOI: 10.1111/ene.12204] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2013] [Accepted: 04/30/2013] [Indexed: 11/29/2022]
Affiliation(s)
- O. Outteryck
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | | | - B. Brochet
- Neurologie; CHU Pellegrin; Bordeaux France
| | - L. Rumbach
- Neurologie; CHU Besançon; Besançon France
| | | | | | - H. Zéphir
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | | | - E. Berger
- Neurologie; CHU Besançon; Besançon France
| | - M. Cohen
- Neurologie; Hôpital Pasteur; Nice France
| | | | | | | | - P. Cabre
- Neurologie; CHU Fort de France; Fort de France France
| | - J. Pelletier
- Neurologie; Hôpital de la Timone; Marseille France
| | - A. Rico
- Neurologie; Hôpital de la Timone; Marseille France
| | - G. Defer
- Neurologie; CHU Caen; Caen France
| | | | - W. Camu
- Neurologie; CHU Montpellier; Montpellier France
| | | | | | | | | | - P. Labauge
- Neurologie; CHU Montpellier; Montpellier France
| | | | - P. Clavelou
- Neurologie; CHRU Clermont Ferrand; Clermont Ferrand France
| | - O. Casez
- Neurologie; CHU Grenoble; Grenoble France
| | | | - C. Papeix
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - C. Lubetzki
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - B. Fontaine
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - N. Couturier
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - N. Bohossian
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - M. Clanet
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - P. Vermersch
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | - J. de Sèze
- Neurologie; Hôpital Civil; Strasbourg France
| | - D. Brassat
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | | |
Collapse
|
47
|
Riant F, Bergametti F, Fournier HD, Chapon F, Michalak-Provost S, Cecillon M, Lejeune P, Hosseini H, Choe C, Orth M, Bernreuther C, Boulday G, Denier C, Labauge P, Tournier-Lasserve E. CCM3 Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas. Mol Syndromol 2013; 4:165-72. [PMID: 23801932 DOI: 10.1159/000350042] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2013] [Indexed: 11/19/2022] Open
Abstract
Mutations of CCM3/PDCD10 cause 10-15% of hereditary cerebral cavernous malformations. The phenotypic characterization of CCM3-mutated patients has been hampered by the limited number of patients harboring a mutation in this gene. This is the first report on molecular and clinical features of a large cohort of CCM3 patients. Molecular screening for point mutations and deletions was used to identify 54 CCM3-mutated index patients. Age at referral and clinical onset, type of inaugural events and presence of extra-axial lesions were investigated in these 54 index patients and 22 of their mutated relatives. Mean age at clinical onset was 23.0 ± 16 years. Clinical onset occurred before 10 years in 26% of the patients, and cerebral hemorrhage was the initial presentation in 72% of these patients. Multiple extra-axial, dural-based lesions were detected in 7 unrelated patients. These lesions proved to be meningiomas in 3 patients who underwent neurosurgery and pathological examination. This 'multiple meningiomas' phenotype is not associated with a specific CCM3 mutation. Hence, CCM3 mutations are associated with a high risk of early-onset cerebral hemorrhage and with the presence of multiple meningiomas.
Collapse
Affiliation(s)
- F Riant
- Service de Génétique Neuro-Vasculaire, Assistance Publique-Hôpitaux de Paris, Paris, France ; Centre de Référence des Maladies Vasculaires Rares du Cerveau et de L'Œil, Groupe Hospitalier Lariboisière - Fernand Widal, Paris, France ; Unité Mixte de Recherche-S-740, Institut National de la Santé et de la Recherche Médicale, Paris, France ; Unité Mixte de Recherche-S-740, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Jeanjean L, Dupeyron G, Labauge P. Rééducation dans le syndrome de Benson. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Bouyon M, Collongues N, Zéphir H, Ballonzoli L, Jeanjean L, Lebrun C, Chanson J, Blanc F, Fleury M, Outteryck O, Defoort S, Labauge P, Vermersch P, Speeg C, De Seze J. Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler 2013; 19:1320-2. [PMID: 23413296 DOI: 10.1177/1352458513476562] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Neuromyelitis optica (NMO) is an inflammatory disease associated with optic neuritis and myelitis. Recently, several studies showed that optical coherence tomography (OCT) could be an interesting method for the evaluation of disease severity; however, to date there are no studies with a longitudinal follow-up of visual function in NMO. The aim of this study was to assess the ability of OCT to evaluate the progression of visual dysfunction in NMO. PATIENTS AND METHODS A group of 30 NMO patients (thus, 60 eyes), comprised of 20 women and 10 men with a mean age of 43.7 +/- 12.3 years, were prospectively evaluated clinically and by a whole neuro-ophthalmological work-up, including: visual acuity (VA), fundoscopy, visual evoked potential (VEP), visual field (VF) and optical coherence tomography (OCT). All patients were tested at baseline (after a mean disease duration of 6.1 years) and after a mean time of follow-up of 18 months (range: 12-36 months). RESULTS Mean VA was similar at the two evaluation times (0.77 +/- 0.36 versus 0.77 +/- 0.35). The mean VF defect decreased slightly, but the difference was not significant (-5.9 +/- 1.3 dB versus -5.3 +/- 1.3 dB). In contrast, the mean retinal thickness seen on OCT decreased from 87.4 +/- 23.3 µm to 79.7 +/- 22.4 µm (p = 0.006). These modifications were only observed in eyes with a past or a recent history of optic neuritis (-15.1 µm; p < 0.001) and not in eyes without any history of optic neuritis (-2.4 µm; not significant). Also, they occurred independently of the occurrence of relapses (n = 13) and especially optic neuritis episodes; however, the number of optic neuritis episodes was low (n = 5). CONCLUSION OCT seems to be a more sensitive test than VA or VF for monitoring ophthalmological function in NMO and it seems to be helpful for the detection of infra-clinical episodes in patients with a past history of optic neuritis. Our results suggest that this easily performed technique should be used in the follow-up of NMO, but complementary studies are warranted to confirm its interest at an individual level.
Collapse
Affiliation(s)
- M Bouyon
- Department of Ophthalmology, Strasbourg University, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ayrignac X, Magnin E, Wallon D, Guennoc AM, Lebrun-Fresnay C, Labauge P. [Vascular leukoencephalopathy in patients without vascular risk factor or NOTCH3 mutation: clinical and radiological findings]. Rev Neurol (Paris) 2013; 169:136-41. [PMID: 23394849 DOI: 10.1016/j.neurol.2012.05.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2012] [Revised: 05/08/2012] [Accepted: 05/29/2012] [Indexed: 11/18/2022]
Abstract
INTRODUCTION White matter lesions seen on MR scan reflect small vessel disease of the brain; increasing age and high blood pressure are the main risk factors. In young patients without vascular risk factors, screening for CADASIL mutation has to be done. Our aim was to describe clinical as well as radiological features of a series of patients without NOTCH3 mutation with severe vascular leukoencephalopathy not explained by the presence of vascular risk factors. MATERIAL AND METHODS Inclusion criteria were grade 3 leukoencephalopathy according to the Fazekas scale, age<70years at onset, and negative screening for NOTCH3 gene. Patients with severe vascular risk factors or atherosclerosis were excluded. Clinical and MRI findings were analysed. RESULTS Eight patients (four men) were included, five did not have any vascular risk factor. Mean age at onset was 59.5years. Initial symptoms were progressive in six cases of eight cases. They consisted of astasia-abasia and progressively worsened; of note one patient died 4years after disease onset. Cerebral MRI disclosed marked atrophy in five patients out of eight, temporal lobe (two out of eight) and external capsule (five out of eight) involvement was moderate. Four patients did not have any other atherosclerosis lesion. Seven out of eight had no retinal microangiopathy. High blood pressure was identified in two patients. CONCLUSION The identification of vascular leukoencephalopathy in young patients without any vascular risk factors should lead the clinician to perform a complete work-up to search for treatable conditions including high blood pressure. Patients with vascular leukoencephalopathy usually present with astasia-abasia. In this context, cerebral MRI, cannot perfectly discriminate between patients with CADASIL from those with acquired small-vessel disease of the brain so that sequencing of NOTCH3 gene exons 2-24 is recommended.
Collapse
Affiliation(s)
- X Ayrignac
- Service de neurologie, hôpital Gui de Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France.
| | | | | | | | | | | |
Collapse
|